Adult O
patients O
with O
anaemia O
( O
Hb O
< O
11 O
g/dL O
) O
were O
randomized O
to O
receive O
epoetin O
beta O
30,000 O
IU O
or O
20,000 O
IU O
once O
weekly O
for O
12 O
weeks O
. O

More B-Claim
patients I-Claim
treated I-Claim
on I-Claim
4 I-Claim
consecutive I-Claim
days I-Claim
reported I-Claim
a I-Claim
clinically I-Claim
meaningful I-Claim
increase I-Claim
in I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
interpretation I-Claim
of I-Claim
these I-Claim
results I-Claim
is I-Claim
challenging I-Claim
due I-Claim
to I-Claim
baseline I-Claim
imbalance I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
. I-Claim

TS O
levels O
were O
available O
for O
147 O
patients O
( O
87.5 O
% O
) O
. O

All O
statistical O
tests O
were O
two-sided O
and O
were O
performed O
at O
the O
alpha O
= O
. O

They O
were O
stratified O
by O
radiotherapy O
( O
early O
, O
late O
, O
or O
none O
) O
, O
stage O
( O
extensive O
or O
limited O
) O
, O
response O
( O
complete O
or O
partial O
) O
, O
and O
cooperative O
group O
( O
National O
Cancer O
Institute O
of O
Canada-Clinical O
Trials O
Group O
or O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
) O
. O

No B-Premise
difference I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
topotecan I-Premise
and I-Premise
observation I-Premise
was I-Premise
observed I-Premise
at I-Premise
any I-Premise
assessment I-Premise
time I-Premise
or I-Premise
for I-Premise
any I-Premise
of I-Premise
the I-Premise
subscale I-Premise
scores I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
reactions I-Premise
, I-Premise
including I-Premise
white I-Premise
blood I-Premise
cell I-Premise
reduction I-Premise
, I-Premise
lower I-Premise
platelet I-Premise
count I-Premise
, I-Premise
lower I-Premise
hemoglobin I-Premise
, I-Premise
and I-Premise
hair I-Premise
loss I-Premise
in I-Premise
the I-Premise
PP I-Premise
group I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
GP I-Premise
group I-Premise
. I-Premise

Extracellular O
adenosine O
5'-triphosphate O
( O
ATP O
) O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
biologic O
processes O
, O
including O
neurotransmission O
, O
muscle O
contraction O
, O
and O
liver O
glucose O
metabolism O
, O
via O
purinergic O
receptors O
. O

Three O
main O
quality O
of O
life O
scales O
( O
general O
health O
status O
, O
functional O
, O
and O
symptom O
scales O
) O
were O
assessed O
and O
compared O
between O
two O
treatment O
groups O
. O

As B-Premise
hypothesized I-Premise
, I-Premise
Bcl-2 I-Premise
levels I-Premise
decreased I-Premise
with I-Premise
CRA/IFN I-Premise
therapy I-Premise
only I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

Frequent B-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
for I-Premise
DCF I-Premise
v I-Premise
CF I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
% I-Premise
v I-Premise
57 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
21 I-Premise
% I-Premise
v I-Premise
27 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
8 I-Premise
% I-Premise
) I-Premise
, I-Premise
lethargy I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

Study O
follow-up O
was O
completed O
July O
2012 O
. O

The B-Premise
CR I-Premise
rate I-Premise
and I-Premise
the I-Premise
3-year I-Premise
CR I-Premise
duration I-Premise
were I-Premise
not I-Premise
affected I-Premise
adversely I-Premise
by I-Premise
use I-Premise
of I-Premise
epoetin I-Premise
alpha I-Premise
. I-Premise

The O
scapula-oriented O
exercises O
were O
designed O
focusing O
on O
scapulothoracic O
movement O
. O

Median B-Premise
survival I-Premise
times I-Premise
were I-Premise
29 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
versus I-Premise
11 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
28 I-Premise
% I-Premise
versus I-Premise
8 I-Premise
% I-Premise
. I-Premise

In B-Premise
the I-Premise
UAE I-Premise
group I-Premise
, I-Premise
mean I-Premise
± I-Premise
standard I-Premise
deviation I-Premise
uterine I-Premise
volume I-Premise
was I-Premise
670 I-Premise
± I-Premise
503 I-Premise
, I-Premise
422 I-Premise
± I-Premise
353 I-Premise
, I-Premise
and I-Premise
292 I-Premise
± I-Premise
287 I-Premise
mL I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
QoL I-Premise
from I-Premise
baseline I-Premise
( I-Premise
t0 I-Premise
) I-Premise
to I-Premise
t1 I-Premise
( I-Premise
RRA I-Premise
period I-Premise
) I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
with I-Premise
significant I-Premise
differences I-Premise
in I-Premise
FACIT-F I-Premise
TOI I-Premise
( I-Premise
P I-Premise
< I-Premise
10 I-Premise
( I-Premise
-3 I-Premise
) I-Premise
) I-Premise
, I-Premise
FACT-G I-Premise
total I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
and I-Premise
FACIT-F I-Premise
total I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

The O
purpose O
of O
our O
study O
is O
to O
compare O
the O
effectiveness O
of O
supportive O
care O
vs. O
3 O
intervention O
approaches O
, O
namely O
oral O
Etoposide O
, O
a O
3-drug O
combination O
, O
and O
radiotherapy O
using O
quality O
of O
life O
( O
QOL O
) O
as O
the O
primary O
measure O
of O
success O
. O

No O
patient O
received O
antiretroviral O
therapy O
. O

Patients B-Premise
treated I-Premise
with I-Premise
gemcitabine-carboplatin I-Premise
reported I-Premise
significantly I-Premise
faster I-Premise
palliation I-Premise
of I-Premise
abdominal I-Premise
symptoms I-Premise
and I-Premise
a I-Premise
significantly I-Premise
improved I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Patients O
assigned O
to O
delayed O
treatment O
continued O
masked O
CA125 O
measurements O
, O
with O
treatment O
commencing O
at O
clinical O
or O
symptomatic O
relapse O
. O

When B-Premise
group I-Premise
1 I-Premise
with I-Premise
group I-Premise
2 I-Premise
were I-Premise
compared I-Premise
, I-Premise
numeric I-Premise
rating I-Premise
scale I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
group I-Premise
1 I-Premise
than I-Premise
in I-Premise
group I-Premise
2 I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but B-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
at I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.68 I-Premise
) I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
) I-Premise
. I-Premise

Patients O
with O
advanced O
HIV-associated O
KS O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
at O
a O
dose O
of O
100 O
mg/m2 O
intravenously O
( O
iv O
) O
every O
2 O
weeks O
or O
PLD O
at O
a O
dose O
of O
20 O
mg/m2 O
iv O
every O
3 O
weeks O
. O

Breast B-Premise
IMRT I-Premise
significantly I-Premise
improved I-Premise
the I-Premise
dose I-Premise
distribution I-Premise
compared I-Premise
with I-Premise
standard I-Premise
radiation I-Premise
. I-Premise

Median B-Premise
survival I-Premise
in I-Premise
the I-Premise
C3 I-Premise
group I-Premise
was I-Premise
28 I-Premise
vs I-Premise
32 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
C6 I-Premise
group I-Premise
( I-Premise
P=0.75 I-Premise
, I-Premise
HR I-Premise
1.04 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.82-1.31 I-Premise
) I-Premise
. I-Premise

Intervention O
group O
patients O
received O
an O
individualized O
fatigue O
education O
and O
support O
program O
delivered O
in O
the O
clinic O
and O
by O
phone O
over O
three O
-10 O
to O
20-minute O
sessions O
1 O
week O
apart O
. O

The O
program O
consisted O
of O
two O
90-minute O
group O
training O
sessions O
, O
a O
brief O
individual O
session O
, O
and O
3 O
follow-up O
telephone O
calls O
. O

No B-Premise
acute I-Premise
Grade I-Premise
4 I-Premise
radiation I-Premise
toxicity I-Premise
developed I-Premise
. I-Premise

At B-Premise
4 I-Premise
years I-Premise
, I-Premise
64 I-Premise
( I-Premise
18 I-Premise
% I-Premise
) I-Premise
of I-Premise
353 I-Premise
patients I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
39 I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
of I-Premise
337 I-Premise
on I-Premise
endocrine-alone I-Premise
therapy I-Premise
had I-Premise
moderate I-Premise
to I-Premise
severe I-Premise
urinary I-Premise
bother I-Premise
( I-Premise
p=0.005 I-Premise
) I-Premise
, I-Premise
and I-Premise
16 I-Premise
( I-Premise
4 I-Premise
% I-Premise
) I-Premise
of I-Premise
355 I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
five I-Premise
( I-Premise
2 I-Premise
% I-Premise
) I-Premise
of I-Premise
338 I-Premise
on I-Premise
endocrine I-Premise
treatment I-Premise
alone I-Premise
had I-Premise
pain I-Premise
while I-Premise
urinating I-Premise
( I-Premise
p=0.024 I-Premise
) I-Premise
. I-Premise

Eligible O
patients O
were O
required O
to O
have O
NSCLC O
unsuitable O
for O
curative O
therapy O
and O
baseline O
hemoglobin O
( O
Hgb O
) O
levels O
less O
than O
121 O
g/L O
. O

A O
total O
of O
358 O
patients O
were O
randomly O
assigned O
between O
July O
2003 O
and O
March O
2005 O
in O
two O
Canadian O
centers O
, O
and O
331 O
were O
included O
in O
the O
analysis O
. O

Median B-Premise
PFS I-Premise
was I-Premise
longest I-Premise
for I-Premise
epidermal I-Premise
growth I-Premise
factor I-Premise
receptor I-Premise
gene I-Premise
( I-Premise
EGFR I-Premise
) I-Premise
-mutated I-Premise
patients I-Premise
in I-Premise
the I-Premise
E I-Premise
group I-Premise
, I-Premise
followed I-Premise
by I-Premise
EGFR-mutated I-Premise
patients I-Premise
in I-Premise
V I-Premise
, I-Premise
EGFR I-Premise
wild I-Premise
type I-Premise
in I-Premise
E I-Premise
, I-Premise
and I-Premise
EGFR I-Premise
wild I-Premise
type I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0034 I-Premise
) I-Premise
. I-Premise

Demographics O
and O
disease O
state O
were O
similar O
between O
groups O
. O

No B-Premise
late I-Premise
arising I-Premise
QOL I-Premise
issues I-Premise
were I-Premise
observed I-Premise
. I-Premise

Seventy-two O
patients O
with O
malignant O
ascites O
were O
divided O
into O
two O
study O
groups O
. O

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
low I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but I-Premise
superior I-Premise
in I-Premise
the I-Premise
FUP I-Premise
arm I-Premise
: I-Premise
12 I-Premise
% I-Premise
versus I-Premise
0 I-Premise
% I-Premise
( I-Premise
intention-to-treat I-Premise
analysis I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Drowsiness B-Premise
, I-Premise
confusion I-Premise
and I-Premise
dry I-Premise
mouth I-Premise
were I-Premise
significantly I-Premise
more I-Premise
intense I-Premise
with I-Premise
amitriptyline I-Premise
than I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.036 I-Premise
, I-Premise
0.003 I-Premise
, I-Premise
and I-Premise
0.034 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

A B-Claim
multidimensional I-Claim
rehabilitation I-Claim
program I-Claim
has I-Claim
statistically I-Claim
and I-Claim
clinically I-Claim
relevant I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
exercise I-Claim
capacity I-Claim
, I-Claim
and I-Claim
muscle I-Claim
force I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
different I-Claim
diagnoses I-Claim
. I-Claim

Possible O
contributing O
factors O
beyond O
the O
efficacy O
of O
the O
intervention O
were O
the O
inability O
of O
patients O
to O
complete O
an O
8-week O
course O
of O
treatment O
and O
return O
in O
a O
timely O
fashion O
for O
follow-up O
assessment O
, O
and O
because O
the O
patients O
may O
have O
only O
had O
weight O
loss O
possible O
not O
related O
to O
cachexia O
, O
but O
other O
causes O
of O
weight O
loss O
, O
such O
as O
decreased O
appetite O
. O

An O
historical O
control O
group O
( O
n O
= O
18 O
) O
without O
exercise O
was O
enrolled O
from O
breast O
cancer O
survivors O
. O

Randomised O
controlled O
trial O
. O

No B-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
groups I-Premise
regarding I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
complications I-Premise
, I-Premise
drainage I-Premise
time I-Premise
, I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
survival I-Premise
. I-Premise

The B-Claim
addition I-Claim
of I-Claim
RT I-Claim
did I-Claim
not I-Claim
negatively I-Claim
impact I-Claim
ED I-Claim
. I-Claim

Intervention O
group O
patients O
received O
the O
Pain O
Education O
Program O
in O
the O
hospital O
, O
and O
3 O
and O
7 O
days O
postdischarge O
by O
telephone O
";" O
this O
was O
done O
by O
nurses O
who O
were O
specially O
trained O
as O
pain O
counselors O
. O

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
was I-Premise
noted I-Premise
( I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
: I-Premise
limited-stage I-Premise
vandetanib I-Premise
patients I-Premise
had I-Premise
longer I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.45 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.07 I-Premise
) I-Premise
and I-Premise
extensive-stage I-Premise
vandetanib I-Premise
patients I-Premise
shorter I-Premise
survival I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
2.27 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.996 I-Premise
) I-Premise
. I-Premise

Therapy B-Premise
with I-Premise
combined I-Premise
bevacizumab I-Premise
plus I-Premise
cisplatin I-Premise
significantly I-Premise
reduced I-Premise
VEGF I-Premise
levels I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Grade B-Claim
2 I-Claim
or I-Claim
higher I-Claim
acute I-Claim
toxicity I-Claim
was I-Claim
more I-Claim
common I-Claim
in I-Claim
the I-Claim
4 I-Claim
day I-Claim
group I-Claim
, I-Claim
approaching I-Claim
statistical I-Claim
significance I-Claim
. I-Claim

Each O
group O
consisted O
of O
40 O
patients O
, O
scheduled O
to O
receive O
treatment O
for O
5 O
min O
, O
three O
times O
a O
week O
. O

This B-Claim
initial I-Claim
evidence I-Claim
involving I-Claim
a I-Claim
small I-Claim
sample I-Claim
size I-Claim
suggests I-Claim
that I-Claim
appropriately I-Claim
designed I-Claim
and I-Claim
supervised I-Claim
resistance I-Claim
exercise I-Claim
may I-Claim
be I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastatic I-Claim
disease I-Claim
and I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
function I-Claim
, I-Claim
physical I-Claim
activity I-Claim
levels I-Claim
and I-Claim
lean I-Claim
mass I-Claim
. I-Claim

To O
study O
the O
effects O
of O
Fuzheng O
Jianpi O
Decoction O
( O
FJD O
) O
combined O
chemotherapy O
on O
the O
quality O
of O
life O
( O
QOL O
) O
and O
the O
survival O
time O
of O
children O
with O
solid O
tumor O
. O

Overall O
278 O
patients O
were O
enrolled O
into O
the O
trial O
. O

Recent O
studies O
suggest O
acupuncture O
may O
be O
effective O
in O
reducing O
vasomotor O
symptoms O
in O
menopausal O
women O
. O

However O
, O
patients B-Premise
with I-Premise
low I-Premise
expression I-Premise
of I-Premise
cytoplasmic I-Premise
pGSK-3β I-Premise
trended I-Premise
toward I-Premise
greater I-Premise
OS I-Premise
with I-Premise
GE I-Premise
treatment I-Premise
. I-Premise

Statistically B-Premise
significantly I-Premise
higher I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
PLD-treated I-Premise
patients I-Premise
at I-Premise
the I-Premise
first I-Premise
and I-Premise
second I-Premise
postbaseline I-Premise
QOL I-Premise
assessments I-Premise
. I-Premise

The B-Premise
incidence I-Premise
and I-Premise
type I-Premise
of I-Premise
adverse I-Premise
events I-Premise
were I-Premise
consistent I-Premise
between I-Premise
the I-Premise
double-blind I-Premise
and I-Premise
cumulative I-Premise
( I-Premise
double-blind I-Premise
plus I-Premise
long-term I-Premise
extension I-Premise
) I-Premise
periods I-Premise
. I-Premise

In O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
SCLC I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim

Compared B-Premise
with I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
standard I-Premise
chemotherapy I-Premise
, I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
capecitabine I-Premise
had I-Premise
significantly I-Premise
better I-Premise
QoL I-Premise
, I-Premise
role I-Premise
function I-Premise
, I-Premise
and I-Premise
social I-Premise
function I-Premise
, I-Premise
fewer I-Premise
systemic I-Premise
adverse I-Premise
effects I-Premise
, I-Premise
less I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
and I-Premise
less I-Premise
fatigue I-Premise
during I-Premise
and I-Premise
at I-Premise
the I-Premise
completion I-Premise
of I-Premise
treatment I-Premise
( I-Premise
P I-Premise
≤ I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Change B-Premise
in I-Premise
self-efficacy I-Premise
for I-Premise
fat I-Premise
restriction I-Premise
partially I-Premise
accounted I-Premise
for I-Premise
the I-Premise
intervention I-Premise
's I-Premise
impact I-Premise
on I-Premise
overall I-Premise
diet I-Premise
quality I-Premise
among I-Premise
men I-Premise
only I-Premise
( I-Premise
mean I-Premise
indirect I-Premise
effect I-Premise
= I-Premise
0.60 I-Premise
) I-Premise
. I-Premise

Best B-Premise
response I-Premise
to I-Premise
induction I-Premise
therapy I-Premise
was I-Premise
complete I-Premise
remission I-Premise
for I-Premise
176 I-Premise
patients I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
, I-Premise
partial I-Premise
remission I-Premise
for I-Premise
341 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
15 I-Premise
patients I-Premise
( I-Premise
3 I-Premise
% I-Premise
) I-Premise
had I-Premise
undergone I-Premise
surgical I-Premise
resection I-Premise
. I-Premise

The O
two O
principal O
aims O
were O
: O
( O
1 O
) O
to O
improve O
the O
survival O
of O
children O
with O
rhabdomyosarcoma O
";" O
and O
( O
2 O
) O
to O
reduce O
the O
late O
effects O
from O
therapy O
by O
restricting O
the O
indications O
for O
surgery O
and/or O
radiotherapy O
after O
good O
response O
to O
initial O
chemotherapy O
. O

Survival O
status O
for O
all O
patients O
was O
determined O
from O
our O
own O
records O
and O
from O
three O
external O
sources O
: O
the O
Hamburg O
cancer O
registry O
, O
family O
doctors O
, O
and O
the O
general O
citizen O
registration O
offices O
. O

The B-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0.63 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0.52-0.75 I-Premise
";" I-Premise
log-rank I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

From O
January O
2002 O
to O
February O
2004 O
, O
102 O
patients O
who O
had O
undergone O
RP O
for O
localized O
or O
locally O
advanced O
prostate O
cancer O
were O
recruited O
and O
randomized O
into O
3 O
groups O
, O
namely O
group O
1-those O
receiving O
only O
150 O
mg O
bicalutamide O
as O
adjuvant O
hormonal O
therapy O
, O
group O
2-those O
receiving O
bicalutamide O
and O
10 O
mg O
tamoxifen O
, O
and O
group O
3-those O
receiving O
bicalutamide O
and O
RT O
. O

Before O
the O
knowledge O
that O
5 O
years O
of O
adjuvant O
tamoxifen O
is O
less O
efficacious O
than O
2 O
to O
3 O
years O
of O
tamoxifen O
followed O
by O
2 O
to O
3 O
years O
of O
anastrozole/exemestane O
, O
we O
designed O
a O
multicenter O
double-blind O
randomized O
controlled O
trial O
in O
women O
taking O
tamoxifen O
with O
a O
thickened O
endometrium O
to O
compare O
uterine O
and O
quality-of-life O
parameters O
between O
those O
switching O
to O
anastrozole O
and O
those O
continuing O
tamoxifen O
. O

In O
this O
study O
, O
we O
aimed O
to O
investigate O
the O
efficacy O
of O
BCAA O
granules O
, O
given O
nocturnally O
, O
in O
improving O
QOL O
in O
these O
patients O
. O

Both O
groups O
were O
well O
matched O
for O
age O
, O
gender O
, O
staging O
, O
adjuvant O
therapy O
, O
and O
mean O
follow-up O
. O

The O
KS O
Functional O
Assessment O
of O
HIV O
( O
FAHI O
) O
quality O
of O
life O
instrument O
was O
used O
before O
and O
after O
every O
other O
treatment O
cycle O
. O

The O
CMA O
intervention O
, O
delivered O
by O
a O
nurse O
practitioner O
, O
focused O
on O
symptom O
assessment O
, O
education O
, O
counseling O
and O
, O
as O
appropriate O
, O
specific O
pharmacologic O
and O
behavioral O
interventions O
for O
each O
of O
the O
three O
target O
symptoms O
. O

From O
1984 O
to O
1989 O
, O
the O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
( O
SAKK O
) O
performed O
a O
randomized O
phase O
III O
trial O
comparing O
early O
versus O
late O
alternating O
chemotherapy O
in O
patients O
with O
small-cell O
lung O
cancer O
. O

Survival B-Premise
and I-Premise
hospital I-Premise
stay I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
groups I-Premise
, I-Premise
whereas I-Premise
overall I-Premise
complications I-Premise
were I-Premise
higher I-Premise
on I-Premise
artificial I-Premise
nutrition I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

The O
online O
program O
, O
Sleep O
Healthy O
Using O
The O
Internet O
, O
delivers O
the O
primary O
components O
of O
CBT-I O
( O
sleep O
restriction O
, O
stimulus O
control O
, O
cognitive O
restructuring O
, O
sleep O
hygiene O
, O
and O
relapse O
prevention O
) O
. O

The B-Premise
Sexual/Relationship I-Premise
Satisfaction I-Premise
subscale I-Premise
was I-Premise
associated I-Premise
with I-Premise
all I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well-being I-Premise
( I-Premise
r=-0.45 I-Premise
to I-Premise
-0.70 I-Premise
, I-Premise
all I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
these O
treatments O
on O
health-related O
quality O
of O
life O
( O
HQL O
) O
. O

Few O
RCT O
exercise O
intervention O
studies O
have O
included O
cancer O
patients O
undergoing O
chemotherapy O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
GCa I-Premise
compared I-Premise
with I-Premise
MIC I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.76 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.61 I-Premise
to I-Premise
0 I-Premise
. I-Premise
93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

These B-Claim
results I-Claim
provide I-Claim
further I-Claim
support I-Claim
for I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
abiraterone I-Claim
in I-Claim
this I-Claim
population I-Claim
. I-Claim

Exercise O
has O
been O
found O
to O
effectively O
decrease O
fatigue O
levels O
and O
improve O
physical O
functioning O
in O
cancer O
patients O
. O

GE O
does O
not O
warrant O
further O
investigation O
in O
unselected O
pancreatic O
cancer O
patients O
. O

infusion O
and O
5-FU O
, O
800 O
mg/m2 O
i.v O
. O

Care O
closer O
to O
home O
is O
being O
explored O
as O
a O
means O
of O
improving O
patient O
experience O
as O
well O
as O
efficiency O
in O
terms O
of O
cost O
savings O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
HRQoL I-Premise
between I-Premise
nurse-led I-Premise
telephone I-Premise
and I-Premise
hospital I-Premise
follow-up I-Premise
at I-Premise
12 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
for I-Premise
difference I-Premise
: I-Premise
-1.93-4.64 I-Premise
) I-Premise
and I-Premise
neither I-Premise
between I-Premise
follow-up I-Premise
with I-Premise
or I-Premise
without I-Premise
EGP I-Premise
( I-Premise
p I-Premise
= I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
for I-Premise
difference I-Premise
: I-Premise
-3.59-3.00 I-Premise
) I-Premise
. I-Premise

The O
effectiveness O
of O
a O
Pain O
Education O
Program O
in O
cancer O
patients O
with O
chronic O
pain O
offered O
by O
nurses O
was O
investigated O
in O
a O
randomized O
controlled O
clinical O
trial O
. O

CONNECT B-Claim
has I-Claim
shown I-Claim
promising I-Claim
indications I-Claim
on I-Claim
health I-Claim
system I-Claim
and I-Claim
patient I-Claim
outcomes I-Claim
that I-Claim
warrant I-Claim
a I-Claim
larger I-Claim
study I-Claim
to I-Claim
further I-Claim
investigate I-Claim
the I-Claim
potential I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

Among B-Premise
the I-Premise
subset I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
there I-Premise
were I-Premise
again I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
. I-Premise

PVI B-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
caused I-Premise
more I-Premise
overall I-Premise
haematological I-Premise
toxicity I-Premise
but I-Premise
CTC I-Premise
grades I-Premise
3/4 I-Premise
was I-Premise
increased I-Premise
only I-Premise
for I-Premise
thrombocytopaenia I-Premise
. I-Premise

After B-Premise
4 I-Premise
weeks I-Premise
of I-Premise
NHT I-Premise
, I-Premise
negative I-Premise
changes I-Premise
of I-Premise
FACT-B I-Premise
and I-Premise
FACT-G I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
group I-Premise
B I-Premise
and I-Premise
C I-Premise
patients I-Premise
, I-Premise
but B-Premise
there I-Premise
were I-Premise
positive I-Premise
changes I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
. I-Premise

Another O
102 O
patients O
, O
97 O
of O
which O
received O
chemotherapy O
, O
were O
subsequently O
included O
in O
the O
study O
on O
an O
individual O
treatment O
preference O
basis O
. O

Patients O
were O
seen O
by O
homeopathic O
providers O
every O
2 O
months O
for O
1 O
year O
. O

After B-Premise
RT I-Premise
, I-Premise
QOL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
.003 I-Premise
) I-Premise
proportionally I-Premise
with I-Premise
improved I-Premise
nutritional I-Premise
intake I-Premise
and I-Premise
status I-Premise
in I-Premise
group I-Premise
1/group I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
worsened I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
maintained I-Premise
or I-Premise
improved I-Premise
overall I-Premise
QOL I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
in I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
maintained I-Premise
or I-Premise
worsened I-Premise
overall I-Premise
QOL I-Premise
. I-Premise

Randomisation O
was O
stratified O
by O
centre O
. O

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
402 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
9.6 I-Premise
months I-Premise
. I-Premise

Patients O
in O
Group O
1 O
performed O
pilates O
and O
home O
exercises O
and O
patients O
in O
group O
2 O
performed O
only O
home O
exercises O
. O

During O
the O
first O
year O
of O
treatment O
, O
HRQOL O
and O
symptoms O
of O
depression O
were O
analyzed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
and O
its O
Endocrine O
Symptom O
Subscale O
( O
ES O
) O
, O
and O
the O
Center O
for O
Epidemiologic O
Studies O
Depression O
Scale O
( O
CES-D O
) O
, O
respectively O
. O

It O
is O
well O
documented O
that O
stress O
is O
associated O
with O
negative O
health O
outcomes O
in O
cancer O
patients O
. O

Adverse B-Claim
events I-Claim
during I-Claim
temozolomide I-Claim
treatment I-Claim
included I-Claim
thrombocytopenia I-Claim
, I-Claim
nausea I-Claim
, I-Claim
vomiting I-Claim
, I-Claim
anorexia I-Claim
, I-Claim
constipation I-Claim
, I-Claim
alopecia I-Claim
, I-Claim
headache I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
convulsions I-Claim
. I-Claim

Patients B-Premise
treated I-Premise
with I-Premise
postoperative I-Premise
RT I-Premise
had I-Premise
better I-Premise
function I-Premise
with I-Premise
higher I-Premise
MSTS I-Premise
( I-Premise
25.8 I-Premise
v I-Premise
21.3 I-Premise
, I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
, I-Premise
TESS I-Premise
( I-Premise
69.8 I-Premise
v I-Premise
60.6 I-Premise
, I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
SF-36 I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
67.7 I-Premise
v I-Premise
58.5 I-Premise
, I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
scores I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise

Severe B-Premise
nonhematologic I-Premise
toxicity I-Premise
was I-Premise
infrequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
including I-Premise
grade I-Premise
3/4 I-Premise
cardiac I-Premise
events I-Premise
( I-Premise
AT I-Premise
, I-Premise
3 I-Premise
% I-Premise
";" I-Premise
AC I-Premise
, I-Premise
4 I-Premise
% I-Premise
) I-Premise
. I-Premise

Before B-Premise
radiotherapy I-Premise
, I-Premise
84 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
erections I-Premise
adequate I-Premise
for I-Premise
intercourse I-Premise
at I-Premise
least I-Premise
a I-Premise
few I-Premise
times I-Premise
during I-Premise
the I-Premise
previous I-Premise
year I-Premise
. I-Premise

After B-Premise
treatment I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
, I-Premise
the I-Premise
body I-Premise
weight I-Premise
was I-Premise
increased I-Premise
in I-Premise
11 I-Premise
patients I-Premise
( I-Premise
20.0 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
28 I-Premise
( I-Premise
50.9 I-Premise
% I-Premise
) I-Premise
and I-Premise
decreased I-Premise
in I-Premise
16 I-Premise
( I-Premise
29.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
it I-Premise
was I-Premise
increased I-Premise
in I-Premise
5 I-Premise
( I-Premise
9.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
26 I-Premise
( I-Premise
49.1 I-Premise
% I-Premise
) I-Premise
and I-Premise
decreased I-Premise
in I-Premise
22 I-Premise
( I-Premise
41.5 I-Premise
% I-Premise
) I-Premise
, I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
, I-Premise
too I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

At B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
initial I-Premise
effects I-Premise
were I-Premise
retained I-Premise
. I-Premise

This O
study O
examined O
factors O
associated O
with O
attrition O
from O
a O
randomized O
controlled O
trial O
comparing O
meaning-centered O
group O
psychotherapy O
( O
MCGP O
) O
, O
an O
intervention O
designed O
to O
help O
advanced O
cancer O
patients O
sustain O
or O
enhance O
their O
sense O
of O
meaning O
to O
the O
supportive O
group O
psychotherapy O
( O
SGP O
) O
, O
a O
standardized O
support O
group O
. O

Patients B-Premise
receiving I-Premise
FLOT I-Premise
exhibited I-Premise
higher I-Premise
response I-Premise
rates I-Premise
and I-Premise
had I-Premise
improved I-Premise
disease-free I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
. I-Premise

To O
address O
this O
barrier O
, O
we O
examined O
the O
ability O
of O
an O
easily O
accessible O
online O
CBT-I O
program O
to O
improve O
insomnia O
symptoms O
in O
cancer O
survivors O
. O

There B-Premise
were I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
interaction I-Premise
effects I-Premise
on I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
with I-Premise
differences I-Premise
being I-Premise
observed I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
and I-Premise
the I-Premise
UC I-Premise
group I-Premise
. I-Premise

Symptoms O
were O
categorized O
as O
none O
, O
mild O
, O
moderate O
, O
or O
severe O
. O

Compared B-Premise
with I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
, I-Premise
the I-Premise
ORR I-Premise
, I-Premise
DCR I-Premise
, I-Premise
and I-Premise
mPFS I-Premise
in I-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
exhibited I-Premise
no I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
significant I-Premise
early I-Premise
attrition I-Premise
due I-Premise
to I-Premise
disease I-Premise
progression I-Premise
";" I-Premise
only I-Premise
61.5 I-Premise
% I-Premise
of I-Premise
patients I-Premise
were I-Premise
alive I-Premise
at I-Premise
2 I-Premise
months I-Premise
. I-Premise

Compliance B-Premise
with I-Premise
QOL I-Premise
was I-Premise
87 I-Premise
% I-Premise
at I-Premise
baseline I-Premise
and I-Premise
more I-Premise
than I-Premise
70 I-Premise
% I-Premise
during I-Premise
treatment I-Premise
. I-Premise

For B-Claim
malignant I-Claim
pleural I-Claim
mesothelioma I-Claim
( I-Claim
MPM I-Claim
) I-Claim
patients I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
maintaining I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQOL I-Claim
) I-Claim
is I-Claim
important I-Claim
. I-Claim

Significant B-Premise
deterioration I-Premise
was I-Premise
noted I-Premise
after I-Premise
chemotherapy I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
in I-Premise
QoL I-Premise
scores I-Premise
, I-Premise
appetite I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
global I-Premise
health I-Premise
status I-Premise
. I-Premise

All O
volunteers O
were O
given O
dl-alpha O
tocopheryl O
acetate O
500 O
mg O
twice O
a O
day O
orally O
plus O
pentoxifylline O
400 O
mg O
twice O
a O
day O
orally O
, O
or O
corresponding O
placebos O
, O
for O
6 O
months O
. O

Unmarried B-Premise
, I-Premise
younger I-Premise
patients I-Premise
who I-Premise
were I-Premise
receiving I-Premise
nontaxane-based I-Premise
therapies I-Premise
and I-Premise
had I-Premise
more I-Premise
advanced I-Premise
disease I-Premise
stage I-Premise
experienced I-Premise
better I-Premise
outcomes I-Premise
. I-Premise

Patients O
had O
metastatic O
CRC O
and O
one O
of O
the O
following O
characteristics O
: O
age O
> O
or O
= O
65 O
years O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
1 O
or O
2 O
, O
serum O
albumin O
< O
or O
= O
3.5 O
g/dL O
, O
or O
prior O
abdominal/pelvic O
radiotherapy O
. O

The O
co-primary O
endpoints O
of O
SATURN O
were O
progression-free O
survival O
( O
PFS O
) O
in O
all O
patients O
and O
in O
those O
with O
positive O
EGFR O
immunohistochemistry O
( O
IHC O
) O
status O
. O

One O
hundred O
patients O
with O
mild-moderate O
pain O
were O
randomized O
to O
treatment O
according O
to O
WHO O
guidelines O
or O
to O
treatment O
with O
strong O
opioids O
. O

The B-Claim
combination I-Claim
of I-Claim
radiotherapy I-Claim
plus I-Claim
6 I-Claim
months I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
provides I-Claim
inferior I-Claim
survival I-Claim
as I-Claim
compared I-Claim
with I-Claim
radiotherapy I-Claim
plus I-Claim
3 I-Claim
years I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
locally I-Claim
advanced I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

However O
, O
the O
survival O
and O
quality-of-life O
( O
QOL O
) O
benefits O
of O
paclitaxel O
used O
as O
a O
single O
agent O
compared O
with O
supportive O
care O
alone O
have O
not O
been O
assessed O
in O
a O
randomized O
clinical O
trial O
. O

Sentinel B-Claim
lymph I-Claim
node I-Claim
biopsy I-Claim
in I-Claim
women I-Claim
with I-Claim
operable I-Claim
breast I-Claim
cancer I-Claim
is I-Claim
routinely I-Claim
used I-Claim
in I-Claim
some I-Claim
countries I-Claim
for I-Claim
staging I-Claim
the I-Claim
axilla I-Claim
despite I-Claim
limited I-Claim
data I-Claim
from I-Claim
randomized I-Claim
trials I-Claim
on I-Claim
morbidity I-Claim
and I-Claim
mortality I-Claim
outcomes I-Claim
. I-Claim

This B-Claim
challenges I-Claim
the I-Claim
current I-Claim
understanding I-Claim
of I-Claim
increasing I-Claim
TMZ I-Claim
dose-intensity I-Claim
by I-Claim
prolonged I-Claim
scheduling I-Claim
. I-Claim

In B-Claim
the I-Claim
watchful-waiting I-Claim
group I-Claim
, I-Claim
side-effects I-Claim
can I-Claim
be I-Claim
caused I-Claim
by I-Claim
tumour I-Claim
progression I-Claim
. I-Claim

For B-Premise
survival I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
, I-Premise
pain I-Premise
, I-Premise
global I-Premise
QL I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
significant I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise

In O
the O
comparison O
of O
responders O
versus O
patients O
with O
both O
SD O
( O
6m O
) O
and O
PD O
, O
responders B-Premise
indicated I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
mood I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
at I-Premise
month I-Premise
3 I-Premise
. I-Premise

Serum O
CA125 O
concentration O
often O
rises O
several O
months O
before O
clinical O
or O
symptomatic O
relapse O
in O
women O
with O
ovarian O
cancer O
. O

Therefore O
, O
we O
compared O
the O
effect O
of O
the O
two O
therapies O
on O
fatigue O
in O
a O
randomised O
controlled O
study O
. O

In B-Claim
patients I-Claim
with I-Claim
cancer I-Claim
, I-Claim
a I-Claim
high-fat I-Claim
diet I-Claim
may I-Claim
possibly I-Claim
support I-Claim
the I-Claim
maintenance I-Claim
of I-Claim
both I-Claim
body I-Claim
weight I-Claim
and I-Claim
body I-Claim
cell I-Claim
mass I-Claim
. I-Claim

Patients O
completed O
questionnaires O
before O
and O
after O
the O
visit O
and O
were O
interviewed O
by O
telephone O
at O
2 O
, O
6 O
, O
and O
12 O
weeks O
. O

Median B-Premise
OS I-Premise
was I-Premise
9.45 I-Premise
and I-Premise
10 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
without I-Premise
statistically I-Premise
a I-Premise
significant I-Premise
difference I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
p=0.259 I-Premise
) I-Premise
. I-Premise

Understanding O
the O
interaction O
between O
gender O
and O
performance O
status O
could O
lead O
to O
better O
prognosticators O
and O
potentially O
could O
tailor O
interventions O
for O
specific O
groups O
of O
patients O
with O
lung O
cancer O
. O

Both B-Premise
groups I-Premise
exhibited I-Premise
significant I-Premise
decreases I-Premise
in I-Premise
hot I-Premise
flashes I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
other I-Premise
quality-of-life I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
mental I-Premise
health I-Premise
from I-Premise
pre- I-Premise
to I-Premise
post-treatment I-Premise
. I-Premise

To O
determine O
the O
incremental O
cost O
utility O
of O
epoetin-alfa O
versus O
placebo O
in O
anaemic O
patients O
with O
stage O
IV O
breast O
cancer O
from O
a O
UK O
National O
Health O
Service O
perspective O
. O

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
once I-Claim
weekly I-Claim
( I-Claim
qw I-Claim
) I-Claim
to I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
chemotherapy I-Claim
increases I-Claim
hemoglobin I-Claim
levels I-Claim
, I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
and I-Claim
reduces I-Claim
transfusions I-Claim
. I-Claim

There B-Claim
is I-Claim
no I-Claim
consensus I-Claim
on I-Claim
an I-Claim
accepted I-Claim
intervention I-Claim
that I-Claim
significantly I-Claim
reduces I-Claim
its I-Claim
severity I-Claim
. I-Claim

When B-Premise
evaluated I-Premise
with I-Premise
the I-Premise
EORTC I-Premise
questionnaire I-Premise
there I-Premise
was I-Premise
significantly I-Premise
less I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P=0.0001 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.03 I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
and I-Premise
peripheral I-Premise
neuropathy I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
in I-Premise
favour I-Premise
of I-Premise
MVC I-Premise
, I-Premise
and I-Premise
a I-Premise
trend I-Premise
for I-Premise
less I-Premise
hair I-Premise
loss I-Premise
( I-Premise
P=0.05 I-Premise
) I-Premise
. I-Premise

Future O
exercise O
trials O
targeting O
these O
responsive O
subgroups O
are O
needed O
to O
confirm O
these O
findings O
. O

Other O
functional O
assessments O
included O
pulmonary O
and O
eating O
functions O
. O

Different B-Claim
analyses I-Claim
yielded I-Claim
slightly I-Claim
different I-Claim
conclusions I-Claim
but O
, O
in B-Claim
general I-Claim
, I-Claim
the I-Claim
QOL I-Claim
analyses I-Claim
were I-Claim
concordant I-Claim
and I-Claim
showed I-Claim
that I-Claim
patients I-Claim
on I-Claim
DOX I-Claim
alone I-Claim
had I-Claim
fewer I-Claim
disease I-Claim
and I-Claim
treatment I-Claim
related I-Claim
adverse I-Claim
events I-Claim
and I-Claim
better I-Claim
QOL I-Claim
. I-Claim

From O
March O
1995 O
until O
April O
1998 O
, O
812 O
patients O
were O
randomly O
assigned O
to O
receive O
three O
or O
four O
cycles O
: O
of O
these O
, O
681 O
were O
also O
randomly O
assigned O
to O
the O
5-day O
or O
the O
3-day O
schedule O
. O

Morbidity B-Claim
associated I-Claim
with I-Claim
wound I-Claim
complications I-Claim
may I-Claim
translate I-Claim
into I-Claim
disability I-Claim
and I-Claim
quality-of-life I-Claim
disadvantages I-Claim
for I-Claim
patients I-Claim
treated I-Claim
with I-Claim
radiotherapy I-Claim
( I-Claim
RT I-Claim
) I-Claim
for I-Claim
soft I-Claim
tissue I-Claim
sarcoma I-Claim
( I-Claim
STS I-Claim
) I-Claim
of I-Claim
the I-Claim
extremities I-Claim
. I-Claim

It O
is O
not O
clear O
whether O
the O
administration O
of O
radioiodine O
provides O
any O
benefit O
to O
patients O
with O
low-risk O
thyroid O
cancer O
after O
a O
complete O
surgical O
resection O
. O

Conducted O
in O
small O
groups O
, O
intervention O
sessions O
were O
offered O
weekly O
for O
4 O
months O
and O
followed O
by O
monthly O
sessions O
for O
8 O
months O
. O

Even O
though O
both B-Premise
treatment I-Premise
modalities I-Premise
resulted I-Premise
in I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
total I-Premise
arm I-Premise
volume I-Premise
( I-Premise
12.2 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
Group I-Premise
II I-Premise
and I-Premise
14.9 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
Group I-Premise
I I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
no B-Premise
significant I-Premise
difference I-Premise
( I-Premise
p=0.582 I-Premise
) I-Premise
was I-Premise
found I-Premise
between I-Premise
those I-Premise
two I-Premise
groups I-Premise
. I-Premise

To O
compare O
dose-volume O
histogram O
variables O
for O
the O
internal O
and O
external O
urinary O
sphincters O
( O
IUS/EUS O
) O
with O
urinary O
quality O
of O
life O
after O
prostate O
brachytherapy O
. O

SLN B-Claim
biopsy I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
procedure I-Claim
. I-Claim

Treatment B-Claim
, I-Claim
particularly I-Claim
the I-Claim
combination I-Claim
therapy I-Claim
, I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
decrease I-Claim
in I-Claim
QOL I-Claim
. I-Claim

The B-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
for I-Premise
marimastat I-Premise
patients I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
4.4 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.81 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
who I-Premise
preferred I-Premise
RET I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
RET I-Premise
compared I-Premise
with I-Premise
UC I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
16.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
4.3-28.7 I-Premise
";" I-Premise
P= I-Premise
.008 I-Premise
) I-Premise
or I-Premise
AET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
11 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.1-23.4 I-Premise
";" I-Premise
P= I-Premise
.076 I-Premise
) I-Premise
. I-Premise

Rehabilitation O
department O
at O
a O
university O
hospital O
. O

Treatment B-Claim
with I-Claim
PB+G I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

With O
the O
adoption O
of O
enhanced O
recovery O
and O
emerging O
new O
modalities O
of O
analgesia O
after O
laparoscopic O
colorectal O
resection O
( O
LCR O
) O
, O
the O
role O
of O
epidural O
analgesia O
has O
been O
questioned O
. O

We O
performed O
a O
prospective O
randomized O
phase O
III O
study O
to O
examine O
whether O
sequential O
administration O
of O
topotecan O
can O
improve O
the O
efficacy O
of O
carboplatin O
and O
paclitaxel O
in O
first-line O
treatment O
of O
advanced O
epithelial O
ovarian O
cancer O
. O

To O
assess O
whether O
omission O
of O
postoperative O
radiotherapy O
in O
women O
with O
'low-risk O
' O
axillary O
node O
negative O
breast O
cancer O
( O
T0-2 O
) O
treated O
by O
breast-conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost-effective O
. O

GEM B-Claim
does I-Claim
not I-Claim
provide I-Claim
an I-Claim
advantage I-Claim
compared I-Claim
with I-Claim
PLD I-Claim
in I-Claim
terms I-Claim
of I-Claim
TTP I-Claim
in I-Claim
ovarian I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
experience I-Claim
recurrence I-Claim
within I-Claim
12 I-Claim
months I-Claim
after I-Claim
primary I-Claim
treatment I-Claim
but I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
spectrum I-Claim
of I-Claim
drugs I-Claim
to I-Claim
be I-Claim
possibly I-Claim
used I-Claim
in I-Claim
the I-Claim
salvage I-Claim
setting I-Claim
. I-Claim

Cosmetic B-Premise
results I-Premise
were I-Premise
better I-Premise
in I-Premise
those I-Premise
not I-Premise
receiving I-Premise
radiotherapy I-Premise
but B-Premise
this I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
be I-Premise
an I-Premise
important I-Premise
issue I-Premise
to I-Premise
the I-Premise
patients I-Premise
. I-Premise

Asymptomatic O
postmenopausal O
women O
who O
took O
adjuvant O
tamoxifen O
for O
2 O
to O
3 O
years O
for O
operable O
breast O
cancer O
with O
a O
double O
endometrial O
thickness O
greater O
than O
7 O
mm O
were O
randomized O
to O
20 O
mg O
tamoxifen O
or O
1 O
mg O
anastrozole O
for O
the O
remaining O
duration O
, O
totaling O
5 O
years O
. O

One O
hundred O
and O
two O
candidates O
with O
CACS O
were O
randomly O
assigned O
to O
two O
treatment O
groups O
( O
trial O
group O
and O
control O
group O
) O
: O
the O
trial O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
plus O
thalidomide O
( O
50 O
mg O
po O
, O
bid O
) O
, O
while O
the O
control O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
alone O
. O

Between O
March O
2007 O
and O
April O
2010 O
, O
151 O
( O
of O
the O
planned O
534 O
) O
patients O
were O
randomised O
( O
75 O
OSC O
+ O
WBRT O
, O
76 O
OSC O
) O
. O

Survival O
differences O
were O
analyzed O
by O
Wilcoxon O
and O
log-rank O
tests O
. O

Therefore B-Claim
, I-Claim
pemetrexed I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
can I-Claim
be I-Claim
used I-Claim
as I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
drug I-Claim
for I-Claim
clinical I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
previously I-Claim
untreated I-Claim
NSCLC I-Claim
. I-Claim

Despite O
premature O
trial O
closure O
, O
our O
data O
provided O
valuable O
insights O
. O

Histologically O
confirmed O
HIV-positive O
patients O
with O
Kaposi O
's O
sarcoma O
were O
randomized O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
either O
radiotherapy O
, O
oral O
Etoposide O
or O
a O
3-drug O
combination O
consisting O
of O
actinomycin-D O
, O
vincristine O
and O
bleomycin O
. O

Analyses B-Claim
by I-Claim
bortezomib I-Claim
dose I-Claim
intensity I-Claim
indicated I-Claim
better I-Claim
HRQoL I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
lower I-Claim
dose I-Claim
intensity I-Claim
. I-Claim

A B-Premise
trend I-Premise
towards I-Premise
increased I-Premise
myelosuppression I-Premise
and I-Premise
infectious I-Premise
complications I-Premise
with I-Premise
TCF I-Premise
versus I-Premise
TC I-Premise
or I-Premise
ECF I-Premise
was I-Premise
observed I-Premise
. I-Premise

Before O
and O
after O
the O
intervention O
period O
, O
all O
of O
the O
subjects O
performed O
a O
cardiorespiratory O
test O
to O
measure O
peak O
oxygen O
uptake O
( O
VO2peak O
) O
, O
a O
dynamic O
strength O
endurance O
test O
( O
maximum O
number O
of O
repetitions O
for O
chest O
and O
leg O
press O
exercise O
at O
30 O
- O
35 O
% O
and O
100 O
- O
110 O
% O
of O
body O
mass O
, O
respectively O
) O
and O
a O
sit-stand O
test O
. O

The B-Premise
linear I-Premise
analogue I-Premise
self-assessment I-Premise
scale I-Premise
was I-Premise
less I-Premise
but I-Premise
significantly I-Premise
efficient I-Premise
for I-Premise
detection I-Premise
of I-Premise
treatment I-Premise
effects I-Premise
, I-Premise
with I-Premise
relative I-Premise
efficiency I-Premise
estimates I-Premise
ranging I-Premise
from I-Premise
0.16 I-Premise
to I-Premise
2.45 I-Premise
and I-Premise
a I-Premise
median I-Premise
of I-Premise
0.66 I-Premise
among I-Premise
the I-Premise
comparisons I-Premise
with I-Premise
relatively I-Premise
stable I-Premise
estimates I-Premise
( I-Premise
/t/ I-Premise
> I-Premise
or I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
and I-Premise
more I-Premise
efficient I-Premise
for I-Premise
recurrence I-Premise
than I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
( I-Premise
5.6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
9 I-Premise
months I-Premise
, I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
1.6 I-Premise
) I-Premise
";" I-Premise
however B-Premise
, I-Premise
this I-Premise
difference I-Premise
may I-Premise
be I-Premise
attributable I-Premise
to I-Premise
the I-Premise
coincidental I-Premise
early I-Premise
death I-Premise
of I-Premise
three I-Premise
patients I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
. I-Premise

Both O
MLD O
with O
compression O
bandage O
( O
complex O
decongestive O
therapy O
) O
group O
( O
Group O
I O
, O
n=15 O
) O
and O
IPC O
with O
SLD O
group O
( O
Group O
II O
, O
n=15 O
) O
received O
treatment O
for O
LE O
3 O
days O
in O
a O
week O
and O
every O
other O
day O
for O
6 O
weeks O
. O

There B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
incompletely I-Premise
infarcted I-Premise
leiomyomas I-Premise
, I-Premise
degree I-Premise
of I-Premise
improvement I-Premise
in I-Premise
symptom I-Premise
score I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
, I-Premise
or I-Premise
QOL I-Premise
. I-Premise

The B-Premise
sample I-Premise
size I-Premise
was I-Premise
small I-Premise
, I-Premise
and I-Premise
patients I-Premise
applied I-Premise
a I-Premise
small I-Premise
amount I-Premise
of I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
half I-Premise
a I-Premise
sachet I-Premise
) I-Premise
to I-Premise
a I-Premise
large I-Premise
surface I-Premise
area I-Premise
. I-Premise

The B-Premise
mean I-Premise
amount I-Premise
of I-Premise
residual I-Premise
tumor I-Premise
tissue I-Premise
was I-Premise
28.9 I-Premise
% I-Premise
for I-Premise
standard I-Premise
surgery I-Premise
( I-Premise
SS I-Premise
) I-Premise
and I-Premise
13.8 I-Premise
% I-Premise
for I-Premise
surgery I-Premise
involving I-Premise
neuronavigation I-Premise
( I-Premise
SN I-Premise
) I-Premise
. I-Premise

Administration O
of O
ESAs O
on O
a O
synchronous O
schedule O
with O
chemotherapy O
administration O
could O
benefit O
patients O
by O
reducing O
clinic O
visits O
and O
potentially O
enhancing O
on-time O
chemotherapy O
delivery O
. O

Toxicity B-Premise
was I-Premise
generally I-Premise
limited I-Premise
to I-Premise
musculoskeletal I-Premise
symptoms I-Premise
( I-Premise
18 I-Premise
% I-Premise
grade I-Premise
3/4 I-Premise
for I-Premise
marimastat I-Premise
) I-Premise
. I-Premise

A O
follow-up O
phone O
call O
after O
72 O
h O
addressed O
individualized O
treatment O
content O
and O
pain O
communication O
. O

The O
trial O
was O
stopped O
for O
futility O
at O
interim O
analysis O
. O

The O
exercise O
group O
followed O
a O
progressive O
, O
8-week O
upper-body O
exercise O
program O
consisting O
of O
resistance O
training O
plus O
aerobic O
exercise O
using O
a O
Monark O
Rehab O
Trainer O
arm O
ergometer O
. O

Although B-Premise
a I-Premise
dosage I-Premise
of I-Premise
50 I-Premise
mg I-Premise
of I-Premise
bicalutamide I-Premise
once I-Premise
daily I-Premise
was I-Premise
not I-Premise
as I-Premise
effective I-Premise
as I-Premise
castration I-Premise
, I-Premise
the B-Claim
favorable I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
and I-Claim
the I-Claim
low I-Claim
incidence I-Claim
of I-Claim
nonhormonal I-Claim
adverse I-Claim
events I-Claim
provide I-Claim
reasons I-Claim
to I-Claim
evaluate I-Claim
bicalutamide I-Claim
, I-Claim
as I-Claim
a I-Claim
single I-Claim
therapeutic I-Claim
agent I-Claim
, I-Claim
at I-Claim
higher I-Claim
doses I-Claim
. I-Claim

Of O
1060 O
registered O
, O
the O
first O
300 O
consecutive O
patients O
were O
included O
in O
the O
current O
utility O
study O
. O

We O
report O
the O
QOL O
results O
of O
JBR.10 O
, O
a O
North O
American O
, O
intergroup O
, O
randomized O
trial O
of O
adjuvant O
cisplatin O
and O
vinorelbine O
compared O
with O
observation O
in O
patients O
who O
have O
completely O
resected O
, O
stages O
IB O
to O
II O
NSCLC O
. O

Furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim

Secondary O
outcomes O
were O
role O
and O
emotional O
functioning O
and O
feelings O
of O
control O
and O
anxiety O
. O

At O
baseline O
, O
groups O
were O
comparable O
for O
age O
( O
mean O
, O
61 O
years O
) O
, O
sex O
( O
54 O
% O
men O
) O
, O
weight O
loss O
( O
32 O
% O
> O
or O
= O
10 O
% O
) O
, O
PS O
( O
13 O
% O
ECOG O
= O
2 O
) O
, O
antineoplastic O
treatment O
( O
50 O
% O
) O
, O
appetite O
( O
mean O
VAS O
score O
, O
31/100 O
mm O
) O
, O
and O
QOL O
( O
mean O
score O
, O
30/100 O
) O
. O

Epoetin B-Premise
alfa I-Premise
recipients I-Premise
had I-Premise
less I-Premise
of I-Premise
a I-Premise
decrease I-Premise
in I-Premise
FACT-An I-Premise
subscale I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
cycle I-Premise
4 I-Premise
and I-Premise
improvement I-Premise
in I-Premise
FACT-An I-Premise
subscale I-Premise
scores I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
assessment I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
. I-Premise

Median B-Premise
survival I-Premise
from I-Premise
randomisation I-Premise
was I-Premise
25·7 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
23·0-27·9 I-Premise
) I-Premise
for I-Premise
patients I-Premise
on I-Premise
early I-Premise
treatment I-Premise
and I-Premise
27·1 I-Premise
months I-Premise
( I-Premise
22·8-30·9 I-Premise
) I-Premise
for I-Premise
those I-Premise
on I-Premise
delayed I-Premise
treatment I-Premise
. I-Premise

Cetuximab B-Claim
offers I-Claim
important I-Claim
HRQL I-Claim
and I-Claim
survival I-Claim
benefits I-Claim
for I-Claim
pretreated I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
, I-Claim
wild-type I-Claim
KRAS I-Claim
CRC I-Claim
. I-Claim

In O
this O
randomised O
controlled O
trial O
, O
we O
recruited O
women O
from O
breast O
clinics O
in O
London O
, O
UK O
, O
who O
had O
problematic O
HFNS O
( O
minimum O
ten O
problematic O
episodes O
a O
week O
) O
after O
breast-cancer O
treatment O
. O

This O
is O
, O
in O
part O
, O
because O
scales O
and O
measures O
of O
QOL O
are O
still O
relatively O
unfamiliar O
to O
most O
clinicians O
and O
because O
population-based O
reference O
ranges O
are O
lacking O
, O
thus O
making O
clinical O
trial O
results O
difficult O
to O
interpret O
. O

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
myelosuppressions I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
GC I-Premise
( I-Premise
anaemia I-Premise
: I-Premise
14 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
2 I-Premise
% I-Premise
PE I-Premise
";" I-Premise
leucopenia I-Premise
: I-Premise
32 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
13 I-Premise
% I-Premise
PE I-Premise
";" I-Premise
thrombocytopenia I-Premise
: I-Premise
22 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
4 I-Premise
% I-Premise
PE I-Premise
) I-Premise
, I-Premise
but B-Premise
these I-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admissions I-Premise
, I-Premise
infections I-Premise
or I-Premise
fatalities I-Premise
. I-Premise

Paired O
t O
tests O
were O
performed O
for O
within-group O
analysis O
. O

Outcomes O
were O
assessed O
at O
baseline O
and O
post O
exercise O
. O

There B-Premise
was I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
non-stent-treated I-Premise
patients I-Premise
( I-Premise
log-rank I-Premise
statistic=4.21 I-Premise
, I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

Outcomes O
measured O
at O
baseline O
and O
weeks O
4 O
, O
27 O
, O
and O
52 O
included O
QOL O
( O
Linear O
Analogue O
Self-Assessment O
( O
LASA O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
( O
FACT-G O
) O
) O
and O
mood O
( O
Profile O
of O
Mood O
States O
( O
POMS O
) O
) O
. O

Primary O
outcomes O
were O
assessed O
as O
follows O
: O
CRF O
using O
the O
Visual O
Analogue O
Scale-Global O
Fatigue O
";" O
physical O
functioning O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality-of-Life O
Core O
30 O
Questionnaire O
, O
and O
CRF-associated O
distress O
using O
the O
Fatigue O
Outcome O
Measure O
. O

Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O

A O
total O
of O
166 O
patients O
were O
randomized O
to O
receive O
intravenous O
5-FU O
( O
450 O
mg/m2/day O
) O
or O
oral O
doxifluridine O
( O
900 O
mg/m2/day O
) O
in O
combination O
with O
leucovorin O
( O
20 O
mg/m2/day O
) O
for O
depth O
of O
invasion O
, O
nodal O
status O
, O
metastasis O
( O
TNM O
) O
stage O
II O
and O
III O
patients O
between O
October O
1997 O
and O
February O
1999 O
. O

Although B-Claim
the I-Claim
regimens I-Claim
in I-Claim
this I-Claim
study I-Claim
were I-Claim
similar I-Claim
in I-Claim
that I-Claim
they I-Claim
included I-Claim
taxane I-Claim
, I-Claim
the I-Claim
mean I-Claim
utility I-Claim
scores I-Claim
and I-Claim
longitudinal I-Claim
patterns I-Claim
of I-Claim
utility I-Claim
scores I-Claim
were I-Claim
different I-Claim
among I-Claim
regimens I-Claim
. I-Claim

This B-Claim
toxicity I-Claim
profile I-Claim
of I-Claim
GE I-Claim
is I-Claim
similar I-Claim
to I-Claim
GP I-Claim
, I-Claim
but B-Claim
the I-Claim
apparent I-Claim
inferior I-Claim
efficacy I-Claim
may I-Claim
discourage I-Claim
further I-Claim
investigation I-Claim
. O

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
other I-Premise
treatment-related I-Premise
side I-Premise
effects I-Premise
between I-Premise
groups I-Premise
. I-Premise

The O
median O
follow-up O
was O
22.6 O
months O
. O

Metastatic B-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
high I-Claim
baseline I-Claim
PSA I-Claim
, I-Claim
pain I-Claim
, I-Claim
and I-Claim
high I-Claim
PSA I-Claim
nadir I-Claim
have I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
with I-Claim
ADT I-Claim
. I-Claim

Of O
449 O
colon O
cancer O
patients O
, O
230 O
underwent O
LAC O
and O
219 O
underwent O
open O
colectomy O
. O

Newly O
diagnosed O
advanced O
cancer O
patients O
undergoing O
radiation O
therapy O
were O
randomized O
to O
active O
QOL O
intervention O
or O
control O
groups O
. O

Patients O
were O
followed O
up O
per-protocol O
";" O
there O
were O
no O
deaths O
, O
and O
five O
patients O
had O
a O
total O
of O
six O
complications O
. O

The B-Premise
mean I-Premise
reduction I-Premise
in I-Premise
AK I-Premise
count I-Premise
was I-Premise
59.2 I-Premise
% I-Premise
for I-Premise
ALA-PDT I-Premise
and I-Premise
41.4 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

The O
consumption O
of O
non-protein O
calories O
did O
not O
differ O
significantly O
between O
the O
two O
patient O
groups O
. O

DPPE B-Claim
( I-Claim
tesmilifene I-Claim
) I-Claim
plus I-Claim
doxorubicin I-Claim
( I-Claim
DOX I-Claim
) I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
survival I-Claim
versus I-Claim
DOX I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
clinical I-Claim
trial I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Systematic B-Claim
assessment I-Claim
of I-Claim
depression I-Claim
is I-Claim
needed I-Claim
in I-Claim
hospice I-Claim
patients I-Claim
. I-Claim

Hence O
, O
equivalence B-Claim
is I-Claim
claimed I-Claim
in I-Claim
this I-Claim
comparison I-Claim
also I-Claim
. I-Claim

The O
treatments O
were O
repeated O
every O
3 O
weeks O
for O
six O
cycles O
";" O
in O
responding O
patients O
, O
an O
additional O
three O
cycles O
of O
single-agent O
carboplatin O
was O
permitted O
. O

No B-Premise
differences I-Premise
were I-Premise
seen I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
for I-Premise
the I-Premise
SF-36 I-Premise
physical I-Premise
and I-Premise
mental I-Premise
component I-Premise
summary I-Premise
scores I-Premise
at I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
24 I-Premise
, I-Premise
and I-Premise
36 I-Premise
months I-Premise
. I-Premise

Of O
698 O
patients O
available O
for O
intention-to-treat O
analysis O
, O
233 O
were O
assigned O
to O
receive O
vinorelbine O
, O
233 O
to O
gemcitabine O
, O
and O
232 O
to O
vinorelbine O
plus O
gemcitabine O
. O

Food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
, I-Premise
but B-Premise
long-term I-Premise
relief I-Premise
of I-Premise
obstructive I-Premise
symptoms I-Premise
was I-Premise
better I-Premise
after I-Premise
GJJ I-Premise
. I-Premise

They O
were O
randomized O
into O
the O
following O
two O
groups O
: O
video-assisted O
thoracic O
surgery O
( O
VATS O
) O
talc O
poudrage O
";" O
and O
talc O
slurry O
( O
TS O
) O
administered O
through O
a O
chest O
tube O
. O

A O
single-item O
linear O
analogue O
self-assessment O
scale O
for O
mood O
was O
compared O
with O
a O
28-item O
adjective O
checklist O
for O
emotional O
well-being O
. O

This B-Claim
study I-Claim
shows I-Claim
that I-Claim
the I-Claim
higher I-Claim
frequency I-Claim
of I-Claim
toxicity I-Claim
associated I-Claim
with I-Claim
MPT I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQoL I-Claim
and I-Claim
that I-Claim
MPT I-Claim
holds I-Claim
a I-Claim
better I-Claim
patient I-Claim
perspective I-Claim
. I-Claim

Individuals B-Premise
receiving I-Premise
duloxetine I-Premise
as I-Premise
their I-Premise
initial I-Premise
5-week I-Premise
treatment I-Premise
reported I-Premise
a I-Premise
mean I-Premise
decrease I-Premise
in I-Premise
average I-Premise
pain I-Premise
of I-Premise
1.06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.72-1.40 I-Premise
) I-Premise
vs I-Premise
0.34 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.01-0.66 I-Premise
) I-Premise
among I-Premise
those I-Premise
who I-Premise
received I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.513 I-Premise
) I-Premise
. I-Premise

HRQOL B-Premise
and I-Premise
symptom I-Premise
relief I-Premise
were I-Premise
equivalent I-Premise
in I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

Intravenous O
5-FU O
and O
oral O
doxifluridine O
were O
compared O
with O
respect O
to O
therapeutic O
efficacy O
, O
drug O
toxicity O
, O
and O
quality O
of O
life O
. O

Fifty-five O
patients O
were O
randomized O
to O
receive O
epoetin O
alpha O
, O
and O
54 O
patients O
received O
no O
epoetin O
. O

The O
most O
likely O
advantage O
of O
LRP O
is O
the O
superior O
cosmetic O
result O
. O

Tumor O
response O
was O
evaluated O
at O
Week O
12 O
and O
Month O
6 O
";" O
progression-free O
patients O
received O
further O
identical O
treatment O
for O
a O
maximum O
of O
3 O
additional O
months O
. O

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
effect I-Premise
on I-Premise
the I-Premise
General I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
score I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
or I-Premise
on I-Premise
any I-Premise
of I-Premise
the I-Premise
individual I-Premise
wellbeing I-Premise
scores I-Premise
";" I-Premise
Physical I-Premise
( I-Premise
P I-Premise
= I-Premise
.13 I-Premise
) I-Premise
, I-Premise
Emotional I-Premise
( I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
, I-Premise
Social I-Premise
( I-Premise
P I-Premise
= I-Premise
.83 I-Premise
) I-Premise
and I-Premise
Functional I-Premise
( I-Premise
P I-Premise
= I-Premise
.26 I-Premise
) I-Premise
. I-Premise

From O
September O
1999 O
to O
April O
2002 O
, O
356 O
patients O
( O
178 O
participants O
received O
gemcitabine-carboplatin O
, O
178 O
received O
carboplatin O
only O
) O
were O
randomized O
to O
treatment O
. O

These B-Claim
results I-Claim
suggest I-Claim
that I-Claim
sexual I-Claim
functioning I-Claim
may I-Claim
require I-Claim
focused I-Claim
assessment I-Claim
by I-Claim
providers I-Claim
, I-Claim
beyond I-Claim
broad I-Claim
QOL I-Claim
assessments I-Claim
, I-Claim
and O
that O
attention B-Claim
to I-Claim
Sexual/Relationship I-Claim
Satisfaction I-Claim
may I-Claim
be I-Claim
critical I-Claim
in I-Claim
the I-Claim
development I-Claim
and I-Claim
implementation I-Claim
of I-Claim
interventions I-Claim
for I-Claim
this I-Claim
cohort I-Claim
of I-Claim
patients I-Claim
. I-Claim

Partial O
responses O
were O
more O
frequent O
in O
patients O
with O
resected O
tumors O
or O
with O
an O
Eastern O
Cooperative O
Oncology O
Group O
PS O
of O
0-1 O
. O

Progression-free B-Premise
survival I-Premise
rates I-Premise
were I-Premise
also I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
HR I-Premise
= I-Premise
1.07 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.92 I-Premise
to I-Premise
1.24 I-Premise
) I-Premise
. I-Premise

We O
enrolled O
1669 O
eligible O
patients O
, O
382 O
( O
23 O
% O
) O
with O
ER-negative O
tumors O
, O
1217 O
( O
73 O
% O
) O
with O
ER-positive O
tumors O
, O
and O
70 O
( O
4 O
% O
) O
with O
unknown O
ER O
status O
. O

Thus B-Premise
far I-Premise
, I-Premise
with I-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
86 I-Premise
weeks I-Premise
, I-Premise
median I-Premise
survival I-Premise
has I-Premise
not I-Premise
been I-Premise
reached I-Premise
in I-Premise
either I-Premise
group I-Premise
. I-Premise

Gastrointestinal B-Premise
and I-Premise
GU I-Premise
toxicity I-Premise
persisted I-Premise
5 I-Premise
years I-Premise
after I-Premise
RT I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
dose I-Premise
schedules I-Premise
other I-Premise
than I-Premise
in I-Premise
regard I-Premise
to I-Premise
urgency I-Premise
of I-Premise
defecation I-Premise
. I-Premise

Multicenter O
, O
randomized O
trial O
. O

The O
goal O
of O
this O
study O
was O
to O
assess O
the O
impact O
of O
neuronavigation O
on O
the O
cytoreductive O
treatment O
of O
solitary O
contrast-enhancing O
intracerebral O
tumors O
and O
outcomes O
of O
this O
treatment O
in O
cases O
in O
which O
neuronavigation O
was O
preoperatively O
judged O
to O
be O
redundant O
. O

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
anorectal I-Premise
manometry I-Premise
and I-Premise
endoanal I-Premise
ultrasound I-Premise
findings I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
coefficient I-Premise
, I-Premise
10.0 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
2.5-17.5 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
, I-Premise
and I-Premise
this I-Premise
effect I-Premise
remained I-Premise
once I-Premise
the I-Premise
confounding I-Premise
effects I-Premise
of I-Premise
mood I-Premise
disturbance I-Premise
and I-Premise
comorbid I-Premise
disorders I-Premise
were I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise

All B-Premise
procedures I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

QoL O
was O
the O
first O
endpoint O
and O
the O
statistical O
power O
was O
inadequate O
to O
assess O
other O
parameters O
. O

The B-Premise
incremental I-Premise
cost-effectiveness I-Premise
ratio I-Premise
was I-Premise
19,39£ I-Premise
per I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
. I-Premise

From O
1994-1999 O
, O
495 O
EKS O
patients O
were O
accrued O
, O
and O
470 O
were O
evaluable O
. O

Of B-Premise
the I-Premise
25 I-Premise
patients I-Premise
in I-Premise
whom I-Premise
3-month I-Premise
MR I-Premise
imaging I-Premise
follow-up I-Premise
was I-Premise
completed I-Premise
, I-Premise
those I-Premise
treated I-Premise
with I-Premise
TAGM I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
complete I-Premise
infarction I-Premise
of I-Premise
all I-Premise
leiomyomas I-Premise
( I-Premise
six I-Premise
patients I-Premise
vs I-Premise
one I-Premise
patient I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
at I-Premise
least I-Premise
90 I-Premise
% I-Premise
tumor I-Premise
infarction I-Premise
( I-Premise
eight I-Premise
patients I-Premise
vs I-Premise
four I-Premise
patients I-Premise
";" I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
had I-Premise
a I-Premise
lower I-Premise
mean I-Premise
percent I-Premise
of I-Premise
residual I-Premise
perfused I-Premise
fibroid I-Premise
tumor I-Premise
tissue I-Premise
( I-Premise
9.6 I-Premise
% I-Premise
vs I-Premise
44.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
compared I-Premise
with I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PVA I-Premise
. I-Premise

Acupuncture B-Claim
is I-Claim
an I-Claim
effective I-Claim
intervention I-Claim
for I-Claim
managing I-Claim
the I-Claim
symptom I-Claim
of I-Claim
CRF I-Claim
and I-Claim
improving I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
weight I-Premise
changes I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
MA I-Premise
( I-Premise
17.1 I-Premise
% I-Premise
v I-Premise
7.6 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

Further B-Claim
research I-Claim
is I-Claim
necessary I-Claim
to I-Claim
confirm I-Claim
this I-Claim
hypothesis I-Claim
in I-Claim
other I-Claim
samples I-Claim
, I-Claim
and I-Claim
causation I-Claim
can I-Claim
not I-Claim
be I-Claim
assumed I-Claim
based I-Claim
on I-Claim
this I-Claim
analysis I-Claim
. I-Claim

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-Anemia I-Premise
or I-Premise
ESAS I-Premise
instruments I-Premise
. I-Premise

With B-Claim
the I-Claim
exception I-Claim
of I-Claim
tumor I-Claim
hemorrhage-type I-Claim
events I-Claim
with I-Claim
gefitinib I-Claim
, I-Claim
the I-Claim
adverse I-Claim
event I-Claim
profiles I-Claim
were I-Claim
generally I-Claim
consistent I-Claim
with I-Claim
those I-Claim
previously I-Claim
observed I-Claim
. I-Claim

However B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
this I-Premise
difference I-Premise
was I-Premise
not I-Premise
helpful I-Premise
in I-Premise
defining I-Premise
which I-Premise
patients I-Premise
were I-Premise
likely I-Premise
to I-Premise
respond I-Premise
. I-Premise

A O
further O
aim O
was O
to O
investigate O
the O
role O
of O
high-dose O
chemotherapy O
in O
young O
patients O
with O
parameningeal O
primary O
tumours O
. O

A O
phase O
III O
trial O
( O
Cancer O
and O
Leukemia O
Group O
B O
CALGB-49907 O
) O
was O
conducted O
to O
test O
whether O
older O
patients O
with O
early-stage O
breast O
cancer O
would O
have O
equivalent O
relapse-free O
and O
overall O
survival O
with O
capecitabine O
compared O
with O
standard O
chemotherapy O
. O

Based O
on O
pattern-mixture O
models O
, O
patients O
who O
dropped O
out O
early O
had O
worse O
QL2 O
decline O
on O
both O
treatments O
. O

Utility B-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
DTX I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
ACP I-Premise
and I-Premise
ACD I-Premise
groups I-Premise
. I-Premise

KP O
, O
toxicity O
, O
and O
SS14 O
lung O
cancer O
specific O
questions O
were O
recorded O
before O
each O
cycle O
of O
treatment O
. O

Overall B-Premise
response I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
42 I-Premise
% I-Premise
for I-Premise
GCa I-Premise
v I-Premise
41 I-Premise
% I-Premise
for I-Premise
MIC I-Premise
";" I-Premise
P I-Premise
= I-Premise
.84 I-Premise
) I-Premise
. I-Premise

Assessments O
were O
made O
on O
4 O
occasions O
: O
at O
baseline O
( O
T0 O
) O
, O
at O
the O
end O
of O
chemotherapy O
( O
T1 O
) O
, O
1 O
month O
after O
chemotherapy O
( O
T2 O
) O
, O
and O
9 O
months O
after O
recruitment O
( O
T3 O
) O
. O

Patient O
data O
regarding O
transfusions O
, O
epoetin-alfa O
usage O
, O
chemotherapy O
treatment O
cycles O
, O
and O
adverse O
events O
were O
recorded O
, O
with O
survival O
follow-up O
for O
12-36 O
months O
post-study O
. O

Total B-Premise
costs I-Premise
per I-Premise
patient I-Premise
were I-Premise
higher I-Premise
for I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro12433 I-Premise
vs. I-Premise
euro8819 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
. I-Premise

However B-Claim
, I-Claim
this I-Claim
combined I-Claim
treatment I-Claim
did I-Claim
not I-Claim
confer I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
treatment I-Claim
with I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5-FU I-Claim
alone I-Claim
for I-Claim
patients I-Claim
with I-Claim
far-advanced I-Claim
CRC I-Claim
";" I-Claim
that I-Claim
might I-Claim
be I-Claim
attributable I-Claim
to I-Claim
the I-Claim
short I-Claim
CDDP I-Claim
administration I-Claim
setting I-Claim
of I-Claim
12 I-Claim
weeks I-Claim
. I-Claim

In B-Claim
endocrine I-Claim
therapy I-Claim
trials I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
patients I-Claim
with I-Claim
response I-Claim
( I-Claim
complete I-Claim
response/partial I-Claim
response I-Claim
[ I-Claim
CR/PR I-Claim
] I-Claim
) I-Claim
and I-Claim
patients I-Claim
with I-Claim
stable I-Claim
disease I-Claim
for I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
( I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
have I-Claim
shown I-Claim
similar I-Claim
survival I-Claim
and I-Claim
therefore I-Claim
are I-Claim
often I-Claim
defined I-Claim
as I-Claim
a I-Claim
population I-Claim
with I-Claim
clinical I-Claim
benefit I-Claim
( I-Claim
patients I-Claim
with I-Claim
CR/PR I-Claim
or I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
. I-Claim

Swallowing O
AUC O
analyses O
were O
calculated O
from O
patient O
diaries O
and O
PDLs O
. O

Many O
women O
with O
breast O
cancer O
need O
psychological O
help O
to O
cope O
more O
effectively O
after O
treatment O
. O

In O
addition O
, O
tumor B-Claim
response I-Claim
was I-Claim
shown I-Claim
to I-Claim
have I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
on I-Claim
QoL I-Claim
indicators I-Claim
. I-Claim

Although O
treatment O
allocation O
was O
random O
in O
only O
19 O
% O
, O
all O
patients O
received O
identical O
information O
in O
a O
multidisciplinary O
setting O
before O
selecting O
RP O
, O
BT O
, O
or O
random O
assignment O
. O

Dosing O
was O
reduced O
to O
25 O
mg/d O
in O
46 O
patients O
( O
43 O
% O
) O
due O
to O
grade O
3/4 O
AEs O
. O

Patients O
in O
the O
control O
arm O
received O
radiotherapy O
only O
. O

However O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
of I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
postoperative I-Premise
complication I-Premise
scores I-Premise
between I-Premise
the I-Premise
2 I-Premise
reconstruction I-Premise
groups I-Premise
. I-Premise

We O
performed O
a O
multicenter O
, O
randomized O
controlled O
trial O
examining O
the O
comparative O
effects O
of O
BCAA O
granules O
given O
orally O
for O
3 O
months O
with O
daytime O
or O
nocturnal O
administration O
in O
patients O
with O
compensated O
cirrhosis O
. O

The B-Claim
postoperative I-Claim
clinical I-Claim
superiority I-Claim
of I-Claim
the I-Claim
interposition I-Claim
of I-Claim
jejunum I-Claim
reconstruction I-Claim
( I-Claim
INT I-Claim
) I-Claim
to I-Claim
Roux-en-Y I-Claim
reconstruction I-Claim
( I-Claim
RY I-Claim
) I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
has I-Claim
not I-Claim
been I-Claim
clarified I-Claim
. I-Claim

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
42 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
( I-Premise
11 I-Premise
months I-Premise
v I-Premise
9.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
and I-Premise
TFS I-Premise
( I-Premise
15 I-Premise
months I-Premise
v I-Premise
11 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
were I-Premise
superior I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
with I-Premise
pamidronate I-Premise
and I-Premise
deteriorated I-Premise
after I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
";" O
secondary O
end O
points O
included O
overall O
response O
rate O
( O
ORR O
) O
and O
progression-free O
survival O
( O
PFS O
) O
. O

In B-Premise
the I-Premise
Cox I-Premise
model I-Premise
, I-Premise
the I-Premise
relative I-Premise
risk I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
was I-Premise
0.70 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
0.51 I-Premise
to I-Premise
0.95 I-Premise
) I-Premise
";" I-Premise
the B-Premise
disease I-Premise
also I-Premise
progressed I-Premise
more I-Premise
slowly I-Premise
in I-Premise
patients I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
. I-Premise

Dietary O
intake O
( O
protein O
, O
energy O
, O
fiber O
) O
assessed O
at O
baseline O
and O
at O
4 O
, O
8 O
, O
and O
12 O
weeks O
after O
starting O
radiotherapy O
. O

In O
445 O
randomly O
assigned O
and O
treated O
patients O
( O
DCF O
= O
221 O
";" O
CF O
= O
224 O
) O
, O
TTP O
was O
longer O
with O
DCF O
versus O
CF O
( O
32 O
% O
risk O
reduction O
";" O
log-rank O
P O
< O
.001 O
) O
. O

Resilience O
, O
perceived O
stress O
, O
anxiety O
, O
and O
quality O
of O
life O
improved O
at O
12 O
weeks O
in O
the O
active O
but O
not O
the O
control O
arm O
. O

Patients B-Premise
with I-Premise
extensive I-Premise
disease I-Premise
survived I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
than I-Premise
on I-Premise
the I-Premise
early I-Premise
alternation I-Premise
regimen I-Premise
( I-Premise
median I-Premise
survival I-Premise
336 I-Premise
days I-Premise
versus I-Premise
301 I-Premise
days I-Premise
, I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Different B-Claim
treatment I-Claim
modalities I-Claim
consisting I-Claim
of I-Claim
MLD I-Claim
and I-Claim
compression I-Claim
bandage I-Claim
( I-Claim
complex I-Claim
decongestive I-Claim
therapy I-Claim
) I-Claim
or I-Claim
IPC I-Claim
and I-Claim
SLD I-Claim
appear I-Claim
to I-Claim
be I-Claim
effective I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
LE I-Claim
with I-Claim
similar I-Claim
therapeutic I-Claim
efficacy I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Median B-Premise
length I-Premise
of I-Premise
stay I-Premise
was I-Premise
4 I-Premise
( I-Premise
range I-Premise
2-35 I-Premise
, I-Premise
interquartile I-Premise
range I-Premise
3-5 I-Premise
) I-Premise
days I-Premise
. I-Premise

Patients O
in O
both O
groups O
had O
similar O
demographic O
and O
clinical O
characteristics O
. O

Participation B-Claim
in I-Claim
an I-Claim
upper-body I-Claim
exercise I-Claim
program I-Claim
caused I-Claim
no I-Claim
changes I-Claim
in I-Claim
arm I-Claim
circumference I-Claim
or I-Claim
arm I-Claim
volume I-Claim
in I-Claim
women I-Claim
with I-Claim
lymphedema I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
and I-Claim
they I-Claim
may I-Claim
have I-Claim
experienced I-Claim
an I-Claim
increase I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The O
starting O
dosage O
was O
60 O
mg/m O
( O
2 O
) O
, O
which O
was O
escalated O
to O
90 O
mg/m O
( O
2 O
) O
and O
then O
120 O
mg/m O
( O
2 O
) O
if O
the O
drug O
was O
well O
tolerated O
( O
< O
or= O
Grade O
2 O
toxicities O
[ O
according O
to O
the O
Southwest O
Oncology O
Group O
toxicity O
scale O
] O
) O
. O

Rates B-Premise
of I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
were I-Premise
25.6 I-Premise
and I-Premise
23.4 I-Premise
per I-Premise
100 I-Premise
patient-years I-Premise
in I-Premise
the I-Premise
double-blind I-Premise
versus I-Premise
cumulative I-Premise
period I-Premise
. I-Premise

The B-Claim
addition I-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
paclitaxel I-Claim
improved I-Claim
progression-free I-Claim
survival I-Claim
( I-Claim
PFS I-Claim
) I-Claim
of I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
( I-Claim
MBC I-Claim
) I-Claim
. I-Claim

Ninety-four O
patients O
were O
evaluable O
for O
efficacy O
and O
safety O
. O

Single-agent O
therapy O
with O
bicalutamide O
, O
a O
nonsteroidal O
antiandrogen O
, O
was O
compared O
with O
castration O
, O
either O
surgical O
or O
medical O
, O
in O
patients O
with O
untreated O
Stage O
D2 O
prostate O
cancer O
. O

Bleomycin O
30 O
mg O
was O
administered O
on O
days O
1 O
, O
8 O
, O
and O
15 O
during O
cycles O
1 O
through O
3 O
. O

infusion O
and O
5-FU O
, O
850 O
mg/m2 O
s O
i.v O
. O

Median O
age O
was O
61.4 O
years O
for O
BT O
and O
59.4 O
for O
RP O
( O
P O
= O
.05 O
) O
. O

Thus B-Claim
, I-Claim
funds I-Claim
permitting I-Claim
, I-Claim
oral I-Claim
Etoposide I-Claim
is I-Claim
a I-Claim
pragmatic I-Claim
approach I-Claim
to I-Claim
treating I-Claim
EKS I-Claim
in I-Claim
an I-Claim
environment I-Claim
where I-Claim
antiretroviral I-Claim
drugs I-Claim
are I-Claim
not I-Claim
universally I-Claim
available I-Claim
. I-Claim

This O
study O
compared O
the O
effect O
of O
two O
doses O
of O
pamidronate O
on O
health-related O
quality O
of O
life O
and O
skeletal O
morbidity O
in O
patients O
with O
newly O
diagnosed O
multiple O
myeloma O
. O

QOL B-Premise
score I-Premise
changes I-Premise
per I-Premise
4-week I-Premise
period I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
showed I-Premise
overall I-Premise
less I-Premise
deterioration I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group-physical I-Premise
scores I-Premise
( I-Premise
-0.2 I-Premise
% I-Premise
versus I-Premise
-2.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
";" I-Premise
functional I-Premise
scores I-Premise
( I-Premise
+0.4 I-Premise
% I-Premise
versus I-Premise
-5.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
";" I-Premise
psychologic I-Premise
scores I-Premise
( I-Premise
-0.7 I-Premise
% I-Premise
versus I-Premise
-2.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.11 I-Premise
) I-Premise
";" I-Premise
overall I-Premise
QOL I-Premise
score I-Premise
( I-Premise
+0.1 I-Premise
% I-Premise
versus I-Premise
-3.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
index I-Premise
scores I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.78 I-Premise
at I-Premise
baseline I-Premise
[ I-Premise
n=267 I-Premise
] I-Premise
, I-Premise
0.79 I-Premise
at I-Premise
eight I-Premise
weeks I-Premise
[ I-Premise
n=186 I-Premise
] I-Premise
, I-Premise
P=0.34 I-Premise
, I-Premise
Wilcoxon I-Premise
signed I-Premise
rank I-Premise
test I-Premise
) I-Premise
, I-Premise
attributable I-Premise
to I-Premise
a I-Premise
modest I-Premise
deterioration I-Premise
of I-Premise
physical I-Premise
function I-Premise
domain I-Premise
scores I-Premise
coincident I-Premise
with I-Premise
small I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
and I-Premise
anxiety/depression I-Premise
scores I-Premise
. I-Premise

We O
conducted O
a O
randomized O
clinical O
trial O
to O
evaluate O
the O
effects O
of O
ATP O
in O
patients O
with O
advanced O
NSCLC O
( O
stage O
IIIB O
or O
IV O
) O
. O

Intention-to-treat B-Premise
analyses I-Premise
indicated I-Premise
that I-Premise
AET I-Premise
resulted I-Premise
in I-Premise
a I-Premise
nonsignificant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.16 I-Premise
) I-Premise
improvement I-Premise
in I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
[ I-Premise
mean I-Premise
group I-Premise
difference I-Premise
= I-Premise
-0.64 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
, I-Premise
-1.56 I-Premise
to I-Premise
+0.27 I-Premise
] I-Premise
. I-Premise

Cetuximab B-Premise
preserved I-Premise
GHS I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-0.2 I-Premise
v I-Premise
-18.1 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Over B-Premise
subsequent I-Premise
assessments I-Premise
, I-Premise
HRQOL I-Premise
was I-Premise
much I-Premise
the I-Premise
same I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

One O
hundred O
and O
twenty-one O
patients O
were O
enrolled O
through O
ten O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
) O
institutions O
";" O
100 O
patients O
had O
breast O
cancer O
and O
21 O
had O
colorectal O
cancer O
. O

The O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
at O
four O
times O
over O
15 O
months O
. O

Secondary O
outcome O
measures O
included O
treatment-associated O
morbidity O
, O
mortality O
, O
survival O
, O
and O
cost-effectiveness O
. O

The O
intervention O
was O
delivered O
on O
an O
individual O
basis O
on O
3 O
occasions O
over O
a O
period O
from O
9 O
weeks O
to O
12 O
weeks O
, O
and O
the O
objective O
of O
the O
intervention O
was O
to O
alter O
fatigue-related O
thoughts O
and O
behavior O
. O

According O
to O
the O
design O
criteria O
, O
palliation O
was O
equivalent O
between O
the O
two O
arms O
. O

Sixteen O
subjects O
were O
randomly O
assigned O
to O
either O
a O
training O
( O
n O
= O
8 O
";" O
age O
: O
50 O
+/- O
5 O
yrs O
) O
or O
control O
non-exercising O
group O
( O
n O
= O
8 O
";" O
age O
: O
51 O
+/- O
10 O
yrs O
) O
. O

Decision O
boundaries O
were O
to O
accept O
the O
null O
hypothesis O
of O
futility O
if O
the O
test O
statistic O
z O
< O
0.39 O
( O
P O
≥ O
.348 O
) O
and O
reject O
the O
null O
hypothesis O
if O
z O
> O
2.54 O
( O
P O
≤ O
.0056 O
) O
. O

Eighteen B-Premise
months I-Premise
after I-Premise
surgery I-Premise
, I-Premise
any I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
LAC I-Premise
or I-Premise
open I-Premise
colectomy I-Premise
favored I-Premise
LAC I-Premise
. I-Premise

The B-Premise
changes I-Premise
between I-Premise
baseline I-Premise
and I-Premise
months I-Premise
5 I-Premise
and I-Premise
7 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
indicated I-Premise
improvement I-Premise
in I-Premise
responders I-Premise
but I-Premise
heterogeneous I-Premise
patterns I-Premise
in I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

This O
double-blind O
, O
randomised O
, O
phase O
3 O
trial O
was O
undertaken O
at O
37 O
clinics O
in O
Denmark O
, O
Norway O
, O
and O
Sweden O
. O

Subjects O
completed O
visual O
analog O
scales O
, O
the O
FACIT-Fatigue O
Scale O
and O
the O
Short O
Form-36v2 O
after O
surgery O
and O
again O
3 O
to O
6 O
months O
after O
hospital O
discharge O
. O

A O
specifically O
designed O
questionnaire O
was O
administered O
at O
three O
months O
to O
assess O
time O
from O
the O
operation O
until O
the O
patient O
was O
able O
to O
walk O
, O
return O
to O
daily O
activities O
, O
or O
sit O
without O
pain O
, O
time O
to O
return O
to O
work O
or O
school O
, O
and O
time O
to O
healing O
. O

No B-Premise
treatment-related I-Premise
deaths I-Premise
occurred I-Premise
. I-Premise

Men O
with O
metastatic O
prostate O
cancer O
( O
n O
= O
161 O
) O
were O
randomized O
to O
receive O
either O
daily O
prednisone O
alone O
or O
mitoxantrone O
( O
every O
3 O
weeks O
) O
plus O
prednisone O
. O

Between O
July O
, O
2001 O
, O
and O
February O
, O
2006 O
, O
189 O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
sertraline O
50 O
mg O
( O
n=95 O
) O
, O
or O
placebo O
( O
n=94 O
) O
, O
once O
per O
day O
. O

Multimodality B-Claim
therapies I-Claim
for I-Claim
cachexia I-Claim
ideally I-Claim
should I-Claim
be I-Claim
introduced I-Claim
within I-Claim
a I-Claim
context I-Claim
of I-Claim
" I-Claim
best I-Claim
supportive I-Claim
care I-Claim
" I-Claim
that I-Claim
includes I-Claim
optimal I-Claim
symptom I-Claim
management I-Claim
and I-Claim
careful I-Claim
psychosocial I-Claim
counseling I-Claim
. I-Claim

In B-Premise
the I-Premise
whole I-Premise
population I-Premise
of I-Premise
patients I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
1-month I-Premise
GI I-Premise
toxicity I-Premise
was I-Premise
not I-Premise
only I-Premise
worse I-Premise
in I-Premise
patients I-Premise
with I-Premise
the I-Premise
hypofractionated I-Premise
RT I-Premise
schedule I-Premise
but I-Premise
also I-Premise
adversely I-Premise
affected I-Premise
daily I-Premise
activities I-Premise
. I-Premise

The O
primary O
endpoint O
was O
survival O
. O

The O
distribution O
of O
bulky O
N2 O
disease O
was O
uniform O
among O
the O
treatment O
arms O
. O

Policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim

Lymphoma O
patients O
commonly O
experience O
declines O
in O
physical O
functioning O
and O
quality O
of O
life O
( O
QoL O
) O
that O
may O
be O
reversed O
with O
exercise O
training O
. O

Median B-Premise
time I-Premise
to I-Premise
first I-Premise
skeletal-related I-Premise
event I-Premise
in I-Premise
patients I-Premise
who I-Premise
had I-Premise
such I-Premise
an I-Premise
event I-Premise
was I-Premise
9·2 I-Premise
months I-Premise
( I-Premise
8·1-10·7 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
10·2 I-Premise
months I-Premise
( I-Premise
7·3-14·0 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
p=0·63 I-Premise
) I-Premise
. I-Premise

Compliance O
with O
QoL O
questionnaires O
was O
88 O
% O
. O

Few O
exercise O
trials O
in O
cancer O
patients O
have O
reported O
longer-term O
follow-up O
. O

The B-Premise
RR I-Premise
was I-Premise
70 I-Premise
% I-Premise
versus I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.3492 I-Premise
) I-Premise
. I-Premise

This O
study O
examined O
how O
PRO O
feedback O
had O
an O
impact O
on O
patient-physician O
communication O
over O
time O
to O
gain O
a O
better O
understanding O
of O
how O
it O
may O
influence O
patient O
care O
. O

Comparison B-Premise
of I-Premise
the I-Premise
population I-Premise
norm I-Premise
and I-Premise
clinical I-Premise
trial I-Premise
data I-Premise
showed I-Premise
that I-Premise
treatment I-Premise
with I-Premise
epoetin I-Premise
alfa I-Premise
resulted I-Premise
in I-Premise
clinically I-Premise
meaningful I-Premise
as I-Premise
well I-Premise
as I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
QOL I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
statistically I-Premise
significant I-Premise
or I-Premise
borderline I-Premise
significant I-Premise
interactions I-Premise
were I-Premise
identified I-Premise
for I-Premise
type I-Premise
of I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
, I-Premise
current I-Premise
treatment I-Premise
status I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.036 I-Premise
) I-Premise
, I-Premise
time I-Premise
since I-Premise
diagnosis I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.010 I-Premise
) I-Premise
, I-Premise
body I-Premise
mass I-Premise
index I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
, I-Premise
and I-Premise
baseline I-Premise
sleep I-Premise
quality I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.041 I-Premise
) I-Premise
. I-Premise

Primary O
endpoint O
was O
overall O
survival O
";" O
secondary O
endpoints O
were O
disease-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Treatment B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
despite I-Claim
the I-Claim
fact I-Claim
that I-Claim
most I-Claim
patients I-Claim
suffered I-Claim
from I-Claim
multiple I-Claim
comorbidities I-Claim
and I-Claim
were I-Claim
heavily I-Claim
pretreated I-Claim
. I-Claim

Patients O
completed O
the O
EORTC O
QLQ O
C30 O
and O
the O
Prostate O
Cancer O
Index O
( O
PCI O
) O
before O
treatment O
and O
at O
1.5 O
, O
3 O
, O
6 O
, O
12 O
, O
18 O
, O
24 O
, O
and O
36 O
months O
post-treatment O
. O

Patient-caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
'unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim

Surgery O
and O
radiotherapy O
commonly O
cause O
adverse O
musculoskeletal O
problems O
, O
particularly O
loss O
of O
strength O
and O
range O
of O
motion O
, O
in O
the O
upper O
quadrant O
of O
breast O
cancer O
patients O
. O

Four B-Claim
cycles I-Claim
of I-Claim
PE I-Claim
induction I-Claim
therapy I-Claim
followed I-Claim
by I-Claim
four I-Claim
cycles I-Claim
of I-Claim
topotecan I-Claim
improved I-Claim
PFS I-Claim
but I-Claim
failed I-Claim
to I-Claim
improve I-Claim
overall I-Claim
survival I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
extensive-stage I-Claim
SCLC I-Claim
. I-Claim

Exploratory O
analyses O
were O
performed O
on O
a O
data O
set O
from O
a O
previous O
study O
. O

Sixteen O
advanced O
cancer O
patients O
with O
neuropathic O
pain O
on O
systemic O
morphine O
therapy O
, O
no O
longer O
receiving O
oncologic O
treatment O
, O
presenting O
moderate O
pain O
( O
about O
4 O
or O
more O
, O
but O
less O
than O
7 O
, O
on O
a O
numerical O
scale O
of O
0-10 O
) O
in O
the O
last O
week O
, O
and O
given O
a O
stable O
morphine O
dose O
in O
the O
last O
2 O
days O
were O
admitted O
to O
the O
study O
. O

The O
patients O
were O
randomized O
to O
either O
daunomycin-cytosine O
arabinoside O
( O
control O
arm O
: O
n O
= O
161 O
) O
or O
daunomycin-cytosine O
arabinoside O
with O
GM-CSF O
( O
GM-CSF O
arm O
: O
n O
= O
157 O
) O
. O

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
except B-Premise
for I-Premise
hair I-Premise
loss I-Premise
. I-Premise

This O
study O
examined O
the O
feasibility O
and O
acceptability O
of O
an O
Individual O
Internet O
Intervention O
( O
III O
) O
embedded O
and O
integrated O
into O
an O
Internet O
Support O
Group O
( O
ISG O
) O
with O
the O
ultimate O
goal O
of O
enhancing O
adherence O
and O
learning O
, O
compared O
with O
an O
individual O
internet O
invention O
alone O
. O

Following O
pretesting O
in O
313 O
patients O
, O
patients O
who O
needed O
district O
nursing O
and O
who O
did O
not O
need O
district O
nursing O
at O
home O
were O
randomly O
assigned O
to O
a O
control O
or O
intervention O
group O
. O

The O
purpose O
of O
this O
2-group O
randomized O
controlled O
pilot O
feasibility O
study O
was O
to O
test O
short-term O
effects O
of O
a O
12-week O
Mindful O
Movement O
Program O
( O
MMP O
) O
intervention O
combining O
mindfulness O
with O
self-directed O
movement O
on O
QOL O
and O
mindfulness O
in O
female O
BCSs O
50 O
years O
or O
older O
and O
at O
12 O
months O
or O
more O
following O
treatment O
. O

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
T3 I-Premise
and I-Premise
T4 I-Premise
assessments I-Premise
. I-Premise

Assessments O
included O
review O
of O
measurable O
metastases O
, O
prostate O
dimensions O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
, O
pain O
, O
analgesic O
requirements O
, O
and O
quality O
of O
life O
responses O
. O

The B-Premise
daytime I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
effect I-Premise
on I-Premise
general I-Premise
health I-Premise
, I-Premise
vitality I-Premise
, I-Premise
social I-Premise
functioning I-Premise
, I-Premise
mental I-Premise
health I-Premise
, I-Premise
and I-Premise
role I-Premise
emotional I-Premise
as I-Premise
revealed I-Premise
on I-Premise
the I-Premise
SF-8 I-Premise
. I-Premise

Herein O
, O
we O
report O
results O
of O
an O
open-label O
, O
multicenter O
phase O
II O
mRCC O
study O
of O
sunitinib O
administered O
on O
a O
continuous O
once-daily O
dosing O
regimen O
. O

Differences B-Premise
were I-Premise
most I-Premise
apparent I-Premise
shortly I-Premise
after I-Premise
the I-Premise
time I-Premise
of I-Premise
completion I-Premise
of I-Premise
radiotherapy I-Premise
. I-Premise

Gynecological O
neoplastic O
disease O
progression O
is O
characterized O
by O
specific O
energy O
metabolism O
alterations O
and O
by O
symptoms O
including O
fatigue O
, O
anorexia O
, O
nausea O
, O
anemia O
, O
and O
immunodepression O
, O
which O
result O
in O
a O
cachexia O
syndrome O
and O
a O
marked O
decrease O
in O
patient O
quality O
of O
life O
( O
QoL O
) O
. O

We O
aimed O
to O
test O
, O
in O
a O
randomized O
controlled O
trial O
, O
the O
clinical O
and O
cost O
effectiveness O
of O
a O
rehabilitation O
intervention O
for O
patients O
with O
advanced O
, O
recurrent O
cancer O
. O

The O
primary O
end-point O
of O
the O
trial O
was O
length O
of O
hospital O
stay O
. O

Randomisation O
was O
by O
use O
of O
a O
computer-generated O
table O
of O
random O
numbers O
in O
blocks O
of O
30 O
. O

The O
purpose O
of O
this O
study O
was O
to O
test O
the O
efficacy O
of O
a O
comprehensive O
menopausal O
assessment O
( O
CMA O
) O
intervention O
program O
in O
achieving O
relief O
of O
symptoms O
, O
the O
improvement O
in O
quality O
of O
life O
( O
QOL O
) O
, O
and O
sexual O
functioning O
in O
breast O
cancer O
survivors O
. O

Our O
purpose O
was O
to O
assess O
the O
impact O
of O
cisplatin O
( O
C O
) O
versus O
cisplatin O
plus O
paclitaxel O
( O
CP O
) O
on O
overall O
QOL O
and O
pain O
in O
cervical O
cancer O
patients O
. O

The B-Premise
inflammation I-Premise
and I-Premise
oxidative I-Premise
stress I-Premise
parameters I-Premise
IL-6 I-Premise
, I-Premise
TNF-α I-Premise
, I-Premise
CRP I-Premise
, I-Premise
and I-Premise
ROS I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
arm I-Premise
1 I-Premise
, I-Premise
while I-Premise
no I-Premise
significant I-Premise
change I-Premise
was I-Premise
observed I-Premise
in I-Premise
arm I-Premise
2 I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
EBRT I-Premise
reported I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
and I-Premise
clinically I-Premise
relevant I-Premise
higher I-Premise
rates I-Premise
of I-Premise
urinary I-Premise
incontinence I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
and I-Premise
fecal I-Premise
leakage I-Premise
leading I-Premise
to I-Premise
more I-Premise
limitations I-Premise
in I-Premise
daily I-Premise
activities I-Premise
. I-Premise

During B-Premise
the I-Premise
last I-Premise
decade I-Premise
, I-Premise
survival I-Premise
rates I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
have I-Premise
increased I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
earlier I-Premise
detection I-Premise
and I-Premise
increased I-Premise
use I-Premise
of I-Premise
adjuvant I-Premise
therapy I-Premise
. I-Premise

The B-Claim
study I-Claim
fails I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
of I-Claim
dl-alpha I-Claim
tocopheryl I-Claim
acetate I-Claim
plus I-Claim
pentoxifylline I-Claim
in I-Claim
patients I-Claim
with I-Claim
arm I-Claim
lymphoedema I-Claim
following I-Claim
axillary I-Claim
surgery I-Claim
and I-Claim
lymphatic I-Claim
radiotherapy I-Claim
, I-Claim
nor I-Claim
does I-Claim
it I-Claim
suggest I-Claim
any I-Claim
benefits I-Claim
of I-Claim
these I-Claim
drugs I-Claim
in I-Claim
radiation-induced I-Claim
induration I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
in I-Claim
the I-Claim
breast I-Claim
, I-Claim
chest I-Claim
wall I-Claim
, I-Claim
pectoral I-Claim
fold I-Claim
, I-Claim
axilla I-Claim
or I-Claim
supraclavicular I-Claim
fossa I-Claim
. I-Claim

A O
total O
of O
60 O
patients O
were O
enrolled O
: O
41 O
patients O
diagnosed O
with O
resectable O
and O
19 O
patients O
diagnosed O
with O
unresectable O
pancreatic O
cancer O
. O

No B-Claim
substantive I-Claim
differences I-Claim
were I-Claim
detected I-Claim
between I-Claim
outcomes I-Claim
of I-Claim
embolization I-Claim
with I-Claim
PVA I-Claim
particles I-Claim
or I-Claim
tris-acryl I-Claim
gelatin I-Claim
microspheres I-Claim
. I-Claim

Supervised B-Claim
group I-Claim
exercise I-Claim
provided I-Claim
functional I-Claim
and I-Claim
psychological I-Claim
benefit I-Claim
after I-Claim
a I-Claim
12 I-Claim
week I-Claim
intervention I-Claim
and I-Claim
six I-Claim
months I-Claim
later I-Claim
. I-Claim

Laparoscopic B-Claim
resection I-Claim
reduced I-Claim
length I-Claim
of I-Claim
hospital I-Claim
stay I-Claim
, I-Claim
improved I-Claim
first-year I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
slightly I-Claim
increased I-Claim
hospital I-Claim
costs I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
pain I-Premise
severity I-Premise
, I-Premise
other I-Premise
postprocedural I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
medication I-Premise
use I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

From B-Premise
the I-Premise
1-year I-Premise
survival I-Premise
analysis I-Premise
, I-Premise
the I-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
probability I-Premise
of I-Premise
death I-Premise
was I-Premise
1.29 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.96 I-Premise
to I-Premise
1.72 I-Premise
) I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
PFS I-Premise
between I-Premise
three I-Premise
and I-Premise
four I-Premise
cycles I-Premise
is I-Premise
-1.0 I-Premise
% I-Premise
( I-Premise
80 I-Premise
% I-Premise
confidence I-Premise
limit I-Premise
[ I-Premise
CL I-Premise
] I-Premise
, I-Premise
-3.8 I-Premise
% I-Premise
, I-Premise
+1.8 I-Premise
% I-Premise
) I-Premise
. I-Premise

Third-generation O
aromatase O
inhibitors O
, O
such O
as O
letrozole O
, O
provide O
a O
new O
option O
for O
extended O
adjuvant O
hormonal O
therapy O
after O
5 O
years O
of O
tamoxifen O
. O

If O
replicated O
in O
larger O
and O
more O
focused O
trials O
, O
aerobic O
exercise O
may O
be O
an O
attractive O
option O
to O
manage O
sleep O
dysfunction O
in O
patients O
with O
cancer O
because O
of O
its O
favorable O
safety O
profile O
and O
other O
documented O
health O
benefits O
. O

The B-Premise
score I-Premise
on I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
of I-Premise
transhiatal I-Premise
patients I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
transthoracic I-Premise
patients I-Premise
in I-Premise
the I-Premise
third I-Premise
, I-Premise
sixth I-Premise
and I-Premise
twelfth I-Premise
month I-Premise
. I-Premise

The O
4 O
arms O
were O
well O
balanced O
for O
sex O
ratio O
, O
age O
, O
WHO O
performance O
status O
, O
the O
primary O
tumour O
site O
and O
prior O
adjuvant O
chemotherapy O
. O

The O
primary O
hypothesis O
was O
that O
duloxetine O
would O
be O
more O
effective O
than O
placebo O
in O
decreasing O
chemotherapy-induced O
peripheral O
neuropathic O
pain O
. O

Percentages O
of O
patients O
completing O
9 O
months O
of O
treatment O
in O
the O
PCV O
, O
TMZ-5 O
, O
and O
TMZ-21 O
arms O
were O
17 O
% O
, O
26 O
% O
, O
and O
13 O
% O
, O
respectively O
. O

The B-Premise
estimated I-Premise
4-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
78.1 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
71.4 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.05 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

Pain O
training O
and O
control O
interventions O
were O
matched O
for O
materials O
and O
method O
. O

We O
aimed O
to O
assess O
the O
effectiveness O
of O
acupuncture O
for O
cancer-related O
fatigue O
( O
CRF O
) O
in O
patients O
with O
breast O
cancer O
. O

It B-Claim
should I-Claim
probably I-Claim
not I-Claim
be I-Claim
tested I-Claim
further I-Claim
, I-Claim
but B-Claim
its I-Claim
antimetabolite I-Claim
schedules I-Claim
and I-Claim
frequent I-Claim
drug I-Claim
administration I-Claim
( I-Claim
ie I-Claim
, I-Claim
dose I-Claim
density I-Claim
) I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
development I-Claim
of I-Claim
new I-Claim
regimens I-Claim
. I-Claim

A O
cancer O
center O
in O
an O
academic O
health O
science O
center O
in O
the O
northeastern O
United O
States O
. O

Cox B-Premise
regression I-Premise
models I-Premise
that I-Premise
took I-Premise
TNM I-Premise
staging I-Premise
or I-Premise
the I-Premise
residual I-Premise
tumor I-Premise
classification I-Premise
and I-Premise
tumor I-Premise
site I-Premise
into I-Premise
account I-Premise
also I-Premise
found I-Premise
significant I-Premise
differences I-Premise
at I-Premise
10 I-Premise
years I-Premise
. I-Premise

Postoperative B-Premise
morbidity I-Premise
rate I-Premise
was I-Premise
28.9 I-Premise
percent I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
vs. I-Premise
40 I-Premise
percent I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.18 I-Premise
) I-Premise
. I-Premise

In B-Premise
this I-Premise
updated I-Premise
final I-Premise
analysis I-Premise
of I-Premise
all I-Premise
patients I-Premise
randomly I-Premise
assigned I-Premise
with I-Premise
strata I-Premise
( I-Premise
n I-Premise
= I-Premise
291 I-Premise
) I-Premise
, I-Premise
lapatinib I-Premise
plus I-Premise
trastuzumab I-Premise
continued I-Premise
to I-Premise
show I-Premise
superiority I-Premise
to I-Premise
lapatinib I-Premise
monotherapy I-Premise
in I-Premise
PFS I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.58 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.011 I-Premise
) I-Premise
and I-Premise
offered I-Premise
significant I-Premise
OS I-Premise
benefit I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.57 I-Premise
to I-Premise
0.97 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.026 I-Premise
) I-Premise
. I-Premise

An O
outcome O
of O
noninferiority O
of O
short-term O
androgen O
suppression O
as O
compared O
with O
long-term O
suppression O
required O
a O
hazard O
ratio O
of O
more O
than O
1.35 O
for O
overall O
survival O
, O
with O
a O
one-sided O
alpha O
level O
of O
0.05 O
. O

A O
multicomponent O
, O
psychoeducational O
intervention O
( O
Project O
ENABLE O
[ O
Educate O
, O
Nurture O
, O
Advise O
, O
Before O
Life O
Ends O
] O
) O
conducted O
by O
advanced O
practice O
nurses O
consisting O
of O
4 O
weekly O
educational O
sessions O
and O
monthly O
follow-up O
sessions O
until O
death O
or O
study O
completion O
( O
n O
= O
161 O
) O
vs O
usual O
care O
( O
n O
= O
161 O
) O
. O

Eight O
hundred O
sixty-one O
patients O
were O
accrued O
from O
89 O
sites O
in O
16 O
countries O
. O

In O
this O
project O
, O
the O
QOL O
differences O
between O
older O
adult O
( O
age O
65 O
) O
and O
younger O
adult O
( O
age O
18-64 O
) O
advanced O
cancer O
patients O
in O
response O
to O
a O
multidisciplinary O
intervention O
designed O
to O
improve O
QOL O
were O
examined O
. O

QoL O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
questionnaire O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
1.01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.77 I-Premise
to I-Premise
1.32 I-Premise
) I-Premise
. I-Premise

Forty-five O
patients O
were O
randomized O
to O
postinduction O
RT O
or O
surgery O
. O

Those O
who O
received O
prednisone O
alone O
could O
have O
mitoxantrone O
added O
after O
6 O
weeks O
if O
there O
was O
no O
improvement O
in O
pain O
. O

Sixty O
consecutive O
radiation O
oncology O
outpatients O
( O
51 O
men O
and O
nine O
women O
";" O
age O
61.9+/-14 O
years O
[ O
mean+/-standard O
deviation O
] O
) O
. O

The B-Premise
most I-Premise
common I-Premise
reason I-Premise
for I-Premise
dropout I-Premise
was I-Premise
patients I-Premise
feeling I-Premise
too I-Premise
ill I-Premise
. I-Premise

Health-related O
quality O
of O
life O
( O
HRQoL O
";" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
. O

The O
aim O
of O
the O
study O
was O
to O
compare O
clinical O
outcomes O
and O
quality O
of O
life O
in O
patients O
undergoing O
surgery O
for O
pilonidal O
disease O
with O
unroofing O
and O
marsupialization O
( O
UM O
) O
or O
rhomboid O
excision O
and O
Limberg O
flap O
( O
RELP O
) O
procedures O
. O

The B-Premise
different I-Premise
schedules I-Premise
of I-Premise
vinorelbine I-Premise
in I-Premise
the I-Premise
two I-Premise
arms I-Premise
led I-Premise
to I-Premise
a I-Premise
greater I-Premise
survival I-Premise
in I-Premise
the I-Premise
NP I-Premise
arm I-Premise
without I-Premise
impairing I-Premise
the I-Premise
tolerance I-Premise
profile I-Premise
, I-Premise
although B-Premise
this I-Premise
is I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

As B-Premise
with I-Premise
previously I-Premise
published I-Premise
results I-Premise
at I-Premise
2 I-Premise
years I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
of I-Premise
the I-Premise
FACT-B I-Premise
, I-Premise
the I-Premise
primary I-Premise
endpoint I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
between I-Premise
treatments I-Premise
at I-Premise
5 I-Premise
years I-Premise
. I-Premise

daily O
";" O
loading-dose O
( O
1200 O
mg O
";" O
Day O
1 O
Cycle O
1 O
only O
) O
and O
G O
1000 O
mg/m O
( O
2 O
) O
i.v O
. O

Primary O
outcome O
measures O
assessed O
spiritual O
well-being O
and O
quality O
of O
life O
";" O
secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
hopelessness O
, O
symptom O
burden O
, O
and O
symptom-related O
distress O
. O

Subcutaneous B-Claim
interleukin-2 I-Claim
and/or I-Claim
interferon-alfa I-Claim
provide I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
in I-Claim
metastatic I-Claim
renal I-Claim
cancers I-Claim
of I-Claim
intermediate I-Claim
prognosis I-Claim
, I-Claim
and I-Claim
they I-Claim
induce I-Claim
a I-Claim
significant I-Claim
risk I-Claim
of I-Claim
toxicity I-Claim
. I-Claim

Improvement B-Premise
was I-Premise
noted I-Premise
in I-Premise
physical I-Premise
capacity I-Premise
: I-Premise
estimated I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
for I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
was I-Premise
0.16 I-Premise
l/min I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.1 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
for I-Premise
muscular I-Premise
strength I-Premise
( I-Premise
leg I-Premise
press I-Premise
) I-Premise
was I-Premise
29.7 I-Premise
kg I-Premise
( I-Premise
23.4 I-Premise
to I-Premise
34.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
recurrence I-Premise
was I-Premise
9/74 I-Premise
( I-Premise
12.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
6/92 I-Premise
( I-Premise
6.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.937 I-Premise
) I-Premise
. I-Premise

Self-report O
questionnaires O
were O
completed O
at O
baseline O
, O
12 O
weeks O
, O
and O
6 O
months O
. O

The B-Premise
treatments I-Premise
gave I-Premise
rise I-Premise
to I-Premise
different I-Premise
rates I-Premise
of I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
3 I-Premise
, I-Premise
4 I-Premise
, I-Premise
11 I-Premise
and I-Premise
14 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
, I-Premise
p I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
, I-Premise
leucopenia I-Premise
and I-Premise
vomiting I-Premise
. I-Premise

In B-Claim
view I-Claim
of I-Claim
the I-Claim
benefits I-Claim
regarding I-Claim
arm I-Claim
functioning I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
the I-Claim
data I-Claim
from I-Claim
this I-Claim
randomised I-Claim
study I-Claim
support I-Claim
the I-Claim
use I-Claim
of I-Claim
SNB I-Claim
in I-Claim
patients I-Claim
with I-Claim
clinically I-Claim
node I-Claim
negative I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Improvements O
in O
FACT-F O
subscale O
score O
were O
significantly O
( O
P O
< O
0.001 O
) O
correlated O
with O
increases O
in O
Hb O
level O
. O

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
response I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
found I-Premise
for I-Premise
any I-Premise
domain I-Premise
or I-Premise
item I-Premise
except I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

FJD B-Claim
combined I-Claim
chemotherapy I-Claim
could I-Claim
effectively I-Claim
improve I-Claim
the I-Claim
QOL I-Claim
of I-Claim
solid I-Claim
tumor I-Claim
children I-Claim
patients I-Claim
, I-Claim
elevate I-Claim
their I-Claim
survival I-Claim
rate I-Claim
, I-Claim
and I-Claim
prolong I-Claim
their I-Claim
life I-Claim
spans I-Claim
. I-Claim

The B-Premise
treatment I-Premise
groups I-Premise
reported I-Premise
improved I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
over I-Premise
time I-Premise
and I-Premise
changes I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
post-intervention I-Premise
were I-Premise
clinically I-Premise
relevant I-Premise
. I-Premise

We O
randomly O
assigned O
75 O
patients O
to O
usual O
care O
and O
227 O
patients O
to O
acupuncture O
plus O
usual O
care O
( O
random O
assignment O
of O
1:3 O
respectively O
) O
with O
minimization O
controlling O
for O
baseline O
general O
fatigue O
and O
maintenance O
treatment O
. O

Efficacy B-Premise
, I-Premise
tolerability I-Premise
, I-Premise
and I-Premise
quality-of-life I-Premise
results I-Premise
were I-Premise
similar I-Premise
between I-Premise
patients I-Premise
dosed I-Premise
in I-Premise
the I-Premise
AM I-Premise
or I-Premise
PM I-Premise
. I-Premise

There B-Claim
is I-Claim
a I-Claim
paucity I-Claim
of I-Claim
high-level I-Claim
evidence I-Claim
on I-Claim
potentially I-Claim
useful I-Claim
interventions I-Claim
and I-Claim
a I-Claim
continued I-Claim
need I-Claim
for I-Claim
new I-Claim
and I-Claim
innovative I-Claim
research I-Claim
, I-Claim
incorporating I-Claim
quality-of-life I-Claim
measurements I-Claim
, I-Claim
in I-Claim
patients I-Claim
experiencing I-Claim
radiation-induced I-Claim
mucositis I-Claim
. I-Claim

The O
trial O
is O
registered O
, O
ISRCTN13771934 O
, O
and O
was O
closed O
March O
15 O
, O
2011 O
. O

However B-Claim
, I-Claim
it I-Claim
provided I-Claim
no I-Claim
improvement I-Claim
in I-Claim
PFS I-Claim
or I-Claim
OS I-Claim
compared I-Claim
with I-Claim
flat I-Claim
dosing I-Claim
. I-Claim

Based B-Premise
on I-Premise
serum I-Premise
rhTSH-stimulated I-Premise
Tg I-Premise
alone I-Premise
( I-Premise
Tg I-Premise
< I-Premise
0.8 I-Premise
microg/l I-Premise
, I-Premise
BRAHMS I-Premise
Tg I-Premise
Kryptor I-Premise
) I-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
ablation I-Premise
success I-Premise
was I-Premise
observed I-Premise
between I-Premise
rhTSH I-Premise
and I-Premise
hypothyroidism I-Premise
groups I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
and I-Premise
97.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Survival O
curves O
were O
calculated O
by O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
with O
the O
Cox O
proportional O
hazards O
model O
. O

Physician O
and O
nurse O
ratings O
were O
closer O
to O
patients O
' O
ratings O
of O
pain O
for O
trained O
versus O
nutrition O
groups O
( O
P=.04 O
and O
< O
.001 O
, O
respectively O
) O
. O

A O
randomized O
phase O
III O
trial O
was O
conducted O
to O
determine O
whether O
combination O
therapy O
with O
13-cis-retinoic O
acid O
( O
13-CRA O
) O
plus O
interferon O
alfa-2a O
( O
IFNalpha2a O
) O
is O
superior O
to O
IFNalpha2a O
alone O
in O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
RCC O
) O
. O

The O
aim O
of O
this O
feasibility O
trial O
was O
to O
determine O
the O
safety O
and O
efficacy O
of O
resistance O
exercise O
by O
prostate O
cancer O
survivors O
with O
bone O
metastatic O
disease O
. O

To O
determine O
the O
feasibility O
of O
administering O
a O
flavonoid-rich O
adjunctive O
treatment O
( O
Concord O
grape O
juice O
) O
for O
the O
management O
of O
chemotherapy-induced O
nausea O
and O
vomiting O
( O
CINV O
) O
";" O
to O
evaluate O
the O
usefulness O
of O
existing O
measures O
for O
assessing O
CINV O
frequency O
and O
severity O
, O
quality O
of O
life O
, O
control O
over O
life O
events O
, O
and O
psychological O
state O
";" O
to O
identify O
any O
actual O
or O
potential O
adverse O
events O
associated O
with O
frequent O
grape O
juice O
intake O
";" O
and O
to O
provide O
preliminary O
data O
concerning O
the O
effect O
of O
Concord O
grape O
juice O
on O
CINV O
, O
quality O
of O
life O
, O
perceived O
control O
over O
life O
events O
, O
and O
psychological O
state O
. O

No B-Premise
QOL I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
arms I-Premise
. I-Premise

Coloplasty B-Claim
pouches I-Claim
resulted I-Claim
in I-Claim
more I-Claim
anastomotic I-Claim
leaks I-Claim
and I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
bowel I-Claim
function I-Claim
. I-Claim

BMD O
of O
48 O
patients O
were O
analyzed O
";" O
23 O
belongs O
to O
group O
A O
, O
10 O
to O
group O
B O
and O
15 O
to O
group O
C. O
The O
serum O
bone O
turnover O
proteins O
bone-specific O
alkaline O
phosphatase O
( O
BAP O
) O
and O
carboxyterminal O
crosslinked O
telopeptide O
of O
type O
I O
collagen O
( O
ICTP O
) O
, O
were O
measured O
with O
commercially O
available O
test O
kits O
before O
treatment O
, O
3 O
months O
and O
15 O
months O
after O
treatment O
. O

Dizziness B-Premise
( I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
and I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
1.2 I-Premise
% I-Premise
vs. I-Premise
5.2 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
less I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

At O
present O
, O
the B-Claim
J-pouch I-Claim
remains I-Claim
the I-Claim
benchmark I-Claim
for I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
, I-Claim
and O
due B-Claim
care I-Claim
( I-Claim
including I-Claim
defunctioning I-Claim
stoma I-Claim
) I-Claim
should I-Claim
be I-Claim
exercised I-Claim
in I-Claim
situations I-Claim
requiring I-Claim
CP I-Claim
. I-Claim

Mood O
was O
measured O
by O
the O
Center O
for O
Epidemiological O
Studies O
Depression O
Scale O
( O
range O
, O
0-60 O
) O
. O

In O
the O
ALND O
group O
, O
positive O
non-SLNs O
were O
found O
in O
18 O
patients O
with O
negative O
SLN O
, O
giving O
a O
FALSE O
negative O
rate O
of O
16.7 O
% O
( O
18 O
of O
108 O
) O
. O

Exemestane B-Premise
patients I-Premise
reported I-Premise
more I-Premise
bone/muscle I-Premise
aches I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

Patients O
with O
advanced O
stage O
IIIB O
or O
IV O
NSCLC O
, O
stratified O
by O
sex O
and O
tumor O
histology O
, O
were O
randomly O
assigned O
1:1 O
to O
paclitaxel O
( O
200 O
mg/m O
( O
2 O
) O
) O
and O
carboplatin O
( O
area O
under O
the O
curve O
, O
6.0 O
) O
with O
or O
without O
ASA404 O
( O
1,800 O
mg O
m O
( O
2 O
) O
) O
, O
given O
intravenously O
once O
every O
3 O
weeks O
for O
six O
cycles O
followed O
by O
maintenance O
ASA404 O
or O
placebo O
. O

Patients O
( O
n O
= O
829 O
) O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
( O
FACT-B+4 O
) O
and O
the O
Spielberger O
State/Trait O
Anxiety O
Inventory O
( O
STAI O
) O
at O
baseline O
( O
pre-surgery O
) O
and O
at O
1 O
, O
3 O
, O
6 O
, O
12 O
, O
and O
18 O
months O
post-surgery O
. O

However O
, O
loss O
of O
power O
was O
not O
an O
issue O
because O
of O
the O
planned O
large O
target O
sample O
size O
. O

From O
January O
, O
2001 O
, O
until O
August O
, O
2005 O
, O
504 O
patients O
were O
randomly O
assigned O
to O
pamidronate O
30 O
mg O
or O
90 O
mg O
( O
252 O
in O
each O
group O
) O
. O

From O
February O
2006 O
to O
March O
2007 O
, O
291 O
patients O
were O
enrolled O
and O
randomized O
, O
after O
total O
thyroidectomy O
: O
( O
1 O
) O
withdrawal O
of O
levothyroxine O
( O
LT4 O
) O
for O
4 O
weeks O
( O
T4-WD O
Group O
, O
n O
= O
89 O
) O
, O
( O
2 O
) O
withdrawal O
of O
LT4 O
for O
4 O
weeks O
plus O
2 O
weeks O
on O
and O
then O
2 O
weeks O
off O
liothyronine O
( O
LT3 O
) O
( O
T3-WD O
Group O
, O
n O
= O
133 O
) O
, O
and O
( O
3 O
) O
rhTSH O
administration O
( O
rhTSH O
Group O
, O
n O
= O
69 O
) O
. O

Recruited O
were O
167 O
solid O
tumor O
children O
patients O
at O
Department O
of O
Tumor O
, O
Beijing O
Children O
's O
Hospital O
. O

The B-Claim
incidence I-Claim
and I-Claim
development I-Claim
of I-Claim
cancer I-Claim
are I-Claim
closely I-Claim
related I-Claim
to I-Claim
dysfunction I-Claim
of I-Claim
immune I-Claim
function I-Claim
. I-Claim

Between O
May O
2003 O
and O
April O
2004 O
, O
98 O
patients O
in O
response O
or O
stable O
disease O
under O
imatinib O
reached O
more O
than O
1 O
year O
of O
follow-up O
. O

Recently B-Claim
, I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
by I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5-fluorouracil I-Claim
( I-Claim
5-FU I-Claim
) I-Claim
with I-Claim
low-dose I-Claim
cisplatin I-Claim
( I-Claim
CDDP I-Claim
) I-Claim
has I-Claim
improved I-Claim
efficacy I-Claim
without I-Claim
severe I-Claim
toxicities I-Claim
. I-Claim

Eligible O
patients O
had O
measurable O
or O
assessable O
disease O
and O
an O
ECOG O
performance O
status O
of O
0 O
to O
2 O
";" O
stable O
brain O
metastases O
were O
allowed O
. O

Treatment O
with O
somatostatin O
analogues O
slowed O
kidney O
growth O
in O
patients O
with O
polycystic O
kidney O
disease O
( O
PKD O
) O
and O
reduced O
liver O
and O
kidney O
volume O
in O
a O
PKD O
rodent O
model O
. O

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
the I-Premise
reduction I-Premise
of I-Premise
incidence/severity I-Premise
of I-Premise
grade I-Premise
1+2 I-Premise
anorexia I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
xerostomia I-Premise
, I-Premise
and I-Premise
dysgeusia I-Premise
was I-Premise
different I-Premise
: I-Premise
90 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
improved I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
67 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
versus I-Premise
51 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Lung O
cancer O
is O
one O
of O
the O
most O
common O
cancers O
in O
the O
United O
States O
and O
is O
associated O
with O
high O
levels O
of O
symptoms O
, O
including O
pain O
, O
fatigue O
, O
shortness O
of O
breath O
, O
and O
psychological O
distress O
. O

The O
randomization O
procedure O
allowed O
some O
investigators O
to O
participate O
only O
in O
the O
comparison O
of O
three O
versus O
four O
cycles O
. O

The O
aim O
of O
this O
prospective O
controlled O
study O
was O
to O
assess O
the O
efficacy O
of O
two O
different O
combination O
treatment O
modalities O
of O
lymphedema O
( O
LE O
) O
. O

Patients O
and O
investigators O
were O
masked O
to O
CA125 O
results O
, O
which O
were O
monitored O
by O
coordinating O
centres O
. O

Biopsies O
( O
n=168 O
) O
were O
taken O
without O
complications O
. O

The O
secondary O
end O
points O
were O
morbidity O
, O
QOL O
, O
and O
functional O
outcome O
. O

This O
phase O
III O
randomized O
trial O
compared O
two O
chemotherapy O
regimens O
, O
gemcitabine O
plus O
carboplatin O
and O
mitomycin O
, O
ifosfamide O
, O
and O
cisplatin O
, O
in O
chemotherapy-naive O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The O
combination O
of O
radiotherapy O
plus O
long-term O
medical O
suppression O
of O
androgens O
( O
> O
or O
= O
2 O
years O
) O
improves O
overall O
survival O
in O
patients O
with O
locally O
advanced O
prostate O
cancer O
. O

Of O
the O
186 O
total O
patients O
, O
113 O
had O
initial O
treatment O
with O
platinum O
therapy O
and O
DNA O
samples O
of O
whom O
46 O
also O
had O
QOL O
data O
. O

There O
was O
also O
no O
difference O
of O
TNM O
stage O
distribution O
and O
type O
of O
operation O
between O
groups O
( O
P O
> O
.05 O
) O
. O

The O
study O
was O
carried O
out O
by O
a O
multi-institutional O
cooperative O
group O
in O
chemotherapy-naive O
stage O
IIIB O
to O
IV O
NSCLC O
patients O
randomized O
to O
receive O
paclitaxel O
plus O
cisplatin O
or O
etoposide O
plus O
cisplatin O
. O

The O
aim O
of O
the O
present O
trial O
was O
to O
evaluate O
the O
effects O
of O
chemotherapy O
on O
the O
quality O
of O
life O
and O
survival O
of O
patients O
with O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
( O
stage O
IIIB O
or O
IV O
) O
. O

Our O
objective O
was O
to O
examine O
the O
effects O
of O
an O
oncologist O
's O
recommendation O
to O
exercise O
on O
self-reported O
exercise O
behavior O
in O
newly O
diagnosed O
breast O
cancer O
survivors O
attending O
their O
first O
adjuvant O
therapy O
consultation O
. O

Compliance O
to O
HRQOL O
assessments O
was O
97 O
% O
at O
baseline O
, O
but O
dropped O
to O
54 O
% O
by O
6 O
months O
. O

Inclusion O
criteria O
were O
inoperable O
, O
disease O
too O
advanced O
for O
curative O
radiotherapy O
, O
and O
chest O
symptoms O
or O
central O
tumor O
threatening O
the O
airways O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
2-year O
functional O
performance O
and O
quality O
of O
life O
in O
patients O
with O
operable O
squamous O
cell O
carcinoma O
of O
the O
esophagus O
, O
who O
have O
received O
either O
surgery O
or O
definitive O
chemoradiation O
( O
CRT O
) O
. O

